The Molecular Basis of Hydrolethalus Syndrome by Honkala, Heli
5 
Heli Honkala
RE
SE
AR
CH
The Molecular Basis of            
Hydrolethalus Syndrome

  
 
 
 
Heli Honkala 
 
THE MOLECULAR BASIS OF            
HYDROLETHALUS SYNDROME  
 
 
 
A C A D E M I C  D I S S E R T A T I O N  
To be presented with the permission of the Faculty of Biosciences,  
University of Helsinki, for public examination in Lecture Hall 2,  
Biomedicum Helsinki, on April 3rd , 2009, at noon. 
 
 
National Public Health Institute 
and 
National Institute for Health and Welfare 
and 
Division of Genetics, Department of Biological and Environmental Sciences,        
Faculty of Biosciences, University of Helsinki 
and 
Helsinki Biomedical Graduate School 
 
Helsinki, Finland 2009 
  
  
 
 
H e l s i n k i  U n i v e r s i t y  B i o m e d i c a l  D i s s e r t a t i o n s  N o .  1 1 8  
ISSN 1457-8433 
 
 
 
 
 
 
 
 
 
 
 
© National Institute for Health and Welfare 
 
ISBN 978- 952-245-034-0 (painettu) 
ISBN 978- 952-245-035-7 (verkkojulkaisu) 
ISSN 1798-0054 (painettu) 
ISSN 1798-0062 (verkkojulkaisu) 
 
Kannen kuva - cover graphic: Heli Honkala 
Yliopistopaino 
Helsinki 2009 
  
 
S u p e r v i s e d  b y  
 
Docent Marjo Kestilä 
Department of Chronic Disease Prevention 
Public Health Genomics 
National Institute for Health and Welfare 
Helsinki, Finland 
 
 
R e v i e w e d  b y  
 
Professor Anna-Elina Lehesjoki 
Folkhälsan Institute of Genetics 
and 
Neuroscience Center, 
University of Helsinki 
Helsinki, Finland 
 
Professor Raili Myllylä 
Department of Biochemistry 
University of Oulu 
Oulu, Finland 
 
 
O p p o n e n t  
 
Docent Sirpa Kivirikko 
HUSLAB Laboratory of Molecular Genetics 
Helsinki University Central Hospital 
Helsinki, Finland 
 
 
C u s t o s  
 
Professor Katarina Pelin 
Department of Biological and Environmental Sciences 
Division of Genetics 
University of Helsinki 
Helsinki, Finland 
 
 
  
 
 
 
    “Don't fear change – embrace it.” 
      Anthony J. D'Angelo 
 
 
 
 
 
 
 
 
 
 
 
To my family 
  
Heli Honkala, The Molecular Basis of Hydrolethalus Syndrome 
Publications of the National Institute for Health and Welfare, 5|2009, 86 Pages 
ISBN 978- 952-245-034-0 (print); 978- 952-245-035-7 (pdf-version) 
ISSN 1798-0054 (print); 1798-0062 (pdf-version) 
http://www.thl.fi 
ABSTRACT 
Hydrolethalus syndrome (HLS) is a severe fetal malformation syndrome that is 
inherited by an autosomal recessive manner. HLS belongs to the Finnish disease 
heritage, an entity of rare diseases that are more prevalent in Finland than in other 
parts of the world. The phenotypic spectrum of the syndrome is wide and it is 
characterized by several developmental abnormalities, including hydrocephalus and 
absent midline structures in the brain, abnormal lobation of the lungs, polydactyly as 
well as micrognathia and other craniofacial anomalies. Polyhydramnios are 
relatively frequent during pregnancy. HLS can nowadays be effectively identified by 
ultrasound scan already at the end of the first trimester of pregnancy. Usually, 
pregnancy is terminated due to the severe developmental defects of the fetus. 
One of the main goals in this thesis was to identify and characterize the gene defect 
underlying HLS. The defect, an A to G point mutation, was found from a previously 
unknown gene that was named HYLS1. Since HYLS1 was an unknown gene with no 
relatives in the known gene families, many functional studies were performed in order 
to unravel the function of the gene and of the protein it codes for. Studies with 
overexpression cell models showed that the subcellular localization of the HYLS1 
protein was different when the wild type and its mutant forms were compared. Wild 
type protein was mainly localized diffusely in the cytoplasm whereas the mutant form 
was observed largely in the nucleus in punctate nuclear inclusions. The wild type form 
was seen to be completely localized in the nucleus when the function of the putative 
nuclear export signal in HYLS1 was blocked. In addition, HYLS1 was shown to 
possess transactivation potential which was significantly diminished in the mutant 
form. When studying possible differences in gene expression in fibroblast cells 
obtained from HLS cases and healthy controls using the microarray method, several 
genes belonging to many different cellular pathways (e.g. lipid metabolism, cell cycle 
regulation, signal transduction) were seen to be differentially expressed. Studies done 
with neuronal progenitor cells revealed that HLS cells had a higher proliferation rate 
and a lower apoptosis rate than control cells. Essential novel information was also 
gathered from studies performed at the tissue level. For example, cholesterol level was 
shown to be significantly elevated in HLS liver samples. 
  
Neuropathological findings of mutation confirmed HLS cases were described for the 
first time in detail in this study. In addition to neuropathological features described 
earlier, such as absent midline structures and a keyhole-like opening in the base of 
the skull, new analyses revealed for example hypothalamic hamartoma as a frequent 
finding. Microscopically, many developmental defects of the central nervous system 
were found, these including cortical dysplasia, rosette structures in the cerebral 
cortex and irregular radial glial cell structures. Also, general pathological findings 
were described which showed an interestingly wide variation in the HLS phenotype. 
At the beginning of this thesis work, HYLS1 was an unknown gene with an 
unknown function. Lots of new information about the function of the gene and the 
protein was obtained in this study although the precise function of HYLS1 remains 
to be elucidated. HYLS1 most likely participates in transcriptional regulation and 
also in the regulation of cholesterol metabolism and the function of HYLS1 is 
critical for normal fetal development. Identification of the gene defect made it 
possible to confirm the HLS diagnosis genetically, an aspect that provides valuable 
information for the families in which a fetus is suspected to have HLS. Studying 
developmental malformation syndromes such as HLS offers essential new 
information also for the understanding of molecular and cellular events required for 
normal fetal development. 
 
Keywords: hydrolethalus syndrome, HYLS1, fetal development, developmental 
disorder, central nervous system 
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TIIVISTELMÄ 
Hydroletalus-oireyhtymä (HLS) on peittyvästi periytyvä, suomalaiseen tauti-
perintöön kuuluva vakava oireyhtymä, joka ilmenee jo sikiönkehityksen aikana ja 
johtaa kuolemaan viimeistään ensimmäisten elinpäivien aikana. Oireyhtymän 
ilmiasun kirjo on laaja ja tyypillisiä piirteitä on useita, näistä yleisimpinä 
keskushermoston epänormaalit rakenteet kuten vesipäisyys ja aivojen keskiviivan 
rakenteiden puutos, keuhkojen epänormaali lohkojako, polydaktylia eli ylimääräiset 
sormet ja varpaat sekä pienileukaisuus ja muut kasvojen rakenteiden poikkeavuudet. 
Lapsiveden määrä loppuraskaudessa on usein moninkertainen normaaliin raskauteen 
verrattuna. Nykyään HLS pystytään tunnistamaan luotettavasti ultraäänitutkimuksen 
avulla jopa jo ensimmäisen raskauskolmanneksen lopulla ja useimmiten päädytään 
raskauden keskeytykseen sikiön vakavien kehityshäiriöiden vuoksi. 
Tämän tutkimuksen yhtenä päätavoitteena oli tunnistaa ja karakterisoida geeni, 
jonka mutaatio johtaa hydroletalus-oireyhtymän syntyyn. Geenivirhe, A-G  
-pistemutaatio, löydettiin aiemmin tuntemattomasta geenistä, jolle annettiin nimi 
HYLS1 oireyhtymän mukaan. HYLS1 oli aiemmin tuntematon geeni eikä se kuulunut 
mihinkään aiemmin tunnettuun geeniperheeseen, joten väitöstyössä tehtiin monia 
toiminnallisia tutkimuksia geenin ja sen koodaaman proteiinin toiminnan 
selvittämiseksi. Solutason tutkimuksissa saatiin selville, että HYLS1-proteiinin 
normaalimuodon ja mutanttimuodon solunsisäinen sijainti on erilainen 
yliekspressiomallissa. Normaali proteiini sijaitsi lähinnä diffuusisti solulimassa, kun 
taas mutanttimuotoa havaittiin laajalti tumassa pistemäisinä rakenteina. Normaalin 
HYLS1-proteiinin nähtiin sijoittuvan tumaan silloin, kun sen mahdollisen 
tumastavientisignaalin toiminta estettiin. Lisäksi HYLS1:lla havaittiin olevan 
transaktivaatio-ominaisuus, joka oli merkittävästi pienentynyt silloin, kun proteiini 
on mutaation seurauksena viallinen. Kun HLS- ja kontrollisikiöiden ihon 
fibroblastisolujen geeniekspressiota tutkittiin mikrosirumenetelmän avulla, 
ilmentymiseroja nähtiin moneen eri signaalireittiin (mm. lipidimetabolia, solusyklin 
säätely, signaalitransduktio) kuuluvissa geeneissä. Solutason jatkotutkimuksissa 
HLS-tapausten hermoston prekursorisolujen havaittiin jakaantuvan kontrollisoluja 
nopeammin, kun taas niiden apoptoosivauhti oli hidastunut. Näiden tulosten lisäksi 
myös kudostasolla tehdyt tutkimukset toivat arvokasta tietoa. Esimerkiksi maksan 
  
kolesterolipitoisuuden havaittiin olevan HLS-tapauksilla huomattavasti kohonnut 
kontrollitapauksiin verrattuna. 
Tämän tutkimuksen aikana kuvattiin myös ensimmäistä kertaa yksityiskohtaiset 
neuropatologiset löydökset HLS-tapauksista, joiden HYLS1-mutaatio oli 
varmennettu. Makroskooppisissa tutkimuksissa aiemmin kuvattujen ja raportoitujen 
löydösten (mm. keskiviivan rakenteiden puutos aivoissa ja HLS:lle tyypillinen 
avaimenreikädefekti kallonpohjassa) lisäksi yleisenä löydöksenä kuvattiin nyt myös 
mm. hypotalaminen hamartooma. Mikroskooppisessa tarkastelussa löydettiin monia 
keskushermoston kehityshäiriöitä, kuten vaillinaisesti kehittynyt aivokuori, 
rosettirakenteet aivokuoressa sekä epänormaalisti järjestyneet radiaaligliasolut. 
Neuropatologisten löydösten lisäksi kuvattiin myös yleiset patologiset löydökset 
yksityiskohtaisesti. Löydösten perusteella voitiin todeta, että HLS:n ilmiasu 
vaihtelee suuresti. 
Väitöstutkimuksen alkaessa HYLS1 oli geeni, jonka toimintaa ei ollut aiemmin 
kartoitettu. Tutkimuksessa saatiin paljon uutta tietoa geenin ja proteiinin toimintaan 
liittyen, vaikka HYLS1:n tarkkaa toimintaa ei vielä tiedetä. Mitä todennäköisimmin 
HYLS1 on solun transkription säätelyyn ja ehkä myös kolesterolimetabolian 
säätelyyn osallistuva proteiini, jolla on hyvin keskeinen tehtävä sikiönkehityksen 
aikana. Geenivirheen tunnistaminen toi tärkeän mahdollisuuden HLS-diagnoosin 
geneettiseen varmistukseen. Tämän myötä voidaan tarjota hyödyllistä geneettistä 
tietoa perheille, joissa epäillään sikiöllä olevan hydroletalus-oireyhtymä. Nyt 
tutkitun oireyhtymän sekä lisäksi muiden harvinaisten oireyhtymien tutkimus 
tarjoavat osaltaan arvokasta uutta tietoa myös normaalin sikiönkehityksen 
tapahtumien tutkimukseen molekyyli- ja solutasolla. 
 
Avainsanat: hydroletalus-oireyhtymä, HYLS1, sikiönkehitys, kehityshäiriö, 
keskushermosto 
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ABBREVIATIONS 
ACAT2  acetyl-Coenzyme A acetyltransferase 2 
ACLS  acrocallosal syndrome 
BrdU  bromodeoxyuridine 
CCND1  cyclin D1 
cDNA  complementary deoxyribonucleic acid 
cM  centiMorgan 
CNF  congenital nephrosis of the Finnish type 
CNS  central nervous system 
COS-1  African green monkey kidney cell line 
CP  choroid plexus 
CSF  cerebrospinal fluid 
DHCR7  7-dehydrocholesterol reductase 
DNA  deoxyribonucleic acid 
EST  expressed sequence tag 
FDH  Finnish disease heritage 
FGF  fibroblast growth factor 
GCPS  Greig cephalopolysyndactyly syndrome 
GLI3  GLI-Kruppel family member 3 
HEK-293 human embryonic kidney cell line  
HH  hedgehog 
HLS  hydrolethalus syndrome 
HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
HYLS1  hydrolethalus syndrome 1 
kb  kilobase 
kDa  kilodalton 
LD  linkage disequilibrium 
LDLR  low density lipoprotein receptor 
LMB  leptomycin B 
MIM  Mendelian inheritance in man 
mRNA  messenger DNA 
NCBI  National Center for Biotechnology Information 
NES  nuclear export signal 
NLS  nuclear localization signal 
NPC  nuclear pore complex 
OFD  orofacio-digital 
ORF  open reading frame 
PBS  phosphate buffer solution 
PCR  polymerase chain reaction 
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PHS  Pallister-Hall syndrome 
pI  isoelectric point 
RNA  ribonucleic acid 
RT  room temperature 
RT-PCR  reverse-transcriptase PCR 
SHH  Sonic hedgehog 
SH-SY5Y human neuroblastoma cell line 
SLOS  Smith-Lemli-Opitz syndrome 
SNP  single nucleotide polymorphism 
SUMO  small ubiquitin-like modifier 
TGF  transforming growth factor 
THBS1  thrombospondin 1 
UCSC  University of California, Santa Cruz 
WNT  Wingless-type 
wt  wild type 
 
 
In addition, the standard abbreviations for nucleotides and amino acids are used. The 
abbreviations of the gene names are written in italics and the protein names in 
regular letters. Human gene names are capitalized, mouse gene names are written in 
lower case letters. Protein names are capitalized. 
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1 INTRODUCTION 
Fetal development is an amazing event with a precisely orchestrated series of 
signaling cascades which control cells to become different tissues and finally, a 
living organism. Defects in these processes can lead to severe developmental 
malformations and to fetal death. 
It is very important to identify any genetic defect behind an inherited disorder since 
even if the studied disease is rare, the results of the multiple functional studies 
performed in the course of research of these entities most probably will offer 
significant information also about the molecular and cellular events and pathways 
required for normal development in general. Also, identification of the defect 
provides a useful tool for confirming the diagnosis and thus, gives essential 
information for families at risk. 
Hydrolethalus syndrome (HLS, MIM 236680) is a lethal malformation syndrome of 
the fetal stage belonging to the group of disorders called the Finnish disease 
heritage. HLS is inherited autosomally recessively and it is enriched in the Finnish 
population with an incidence of at least 1:20,000. HLS is characterized by several 
malformations of the developing organs. In the central nervous system, prominent 
features include absent midline structures and the hydrocephalus. Other hallmark 
features consist of micrognathia, polydactyly of hands and feet, defective lobation of 
the lungs, craniofacial anomalies as well as polyhydramnios during pregnancy. HLS 
was first described in the 1980´s when it was separated from the Meckel syndrome 
(Salonen et al. 1981) and thus, HLS became its own syndrome entity. In addition to 
Finnish cases, some non-Finnish cases resembling HLS have been reported abroad.  
Since the molecular background of HLS had not been characterized before this study, 
the main goal in this study was first to identify the gene and the mutation(s) underlying 
HLS. As the disease-causing mutation was found, subsequent analyses consisted of 
determination of the protein function as well as unraveling the disease pathogenesis of 
HLS with studies both at the cellular and tissue levels. Also, the neuropathological 
picture of this severe syndrome was described in detail for the first time. The general 
pathological findings reported simultaneously with the neuropathological results 
revealed a highly interesting wide phenotypic spectrum in HLS. 
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2 REVIEW OF THE LITERATURE 
2.1 The Finnish disease heritage 
An entity called the Finnish disease heritage (FDH) is a set of inherited conditions 
that are more common in Finland than elsewhere in the world when compared to 
population size (Norio et al. 1973; Perheentupa 1972). Nowadays, 36 disorders are 
included under this definition. All of these disorders are monogenic and relatively 
rare, 32 of them being autosomal recessive, two autosomal dominant and two X-
linked (Norio 2003c). At the same time, some diseases like cystic fibrosis and 
phenylketonuria that are common elsewhere have very low incidence in Finland 
(Guldberg et al. 1995; Kere et al. 1994; Pastinen et al. 2001). 
Almost one third of the conditions in FDH cause some form of mental retardation 
and half of the diseases are lethal at some point of affected´s life. In most cases, 
incidences of the diseases vary from 1:10,000 to 1:100,000 in Finland (Norio 
2003a). As the Finnish gene pool is relatively homogeneous it has proven to be a 
useful tool in finding the disease-causing mutations in the genome (Peltonen et al. 
1999) and in fact, the underlying causative genetic defect are currently reported for 
all of the disorders except for PEHO syndrome (www.findis.org). It has been shown 
that one founder mutation was the main contributor to all these diseases. In most 
diseases, more than 90% of the Finnish patients have the same Finmajor mutation 
causing the disease (Norio 2003c). However, there are also some disorders where 
the frequency of the Finmajor mutation is between 70 and 80% and in addition, other 
mutations have been found at varying frequencies, see e.g. (Huopaniemi et al. 1999; 
Kestilä et al. 1998; Sankila et al. 1992). 
The reason why this unique set of diseases has been enriched in Finland is largely 
due to the population history of this isolated area with its sparseness of population, 
vast forest areas, numerous lakes and partly to pure chance, also, since the ancient 
inhabitants of Finland brought with them a random assortment of possible disease 
mutations (Norio 2003a, 2003b). This assortment stayed largely unchanged because 
the great population migrations did not happen in the northern part of Europe as they 
did in central and southern Europe. Close consanguinities between parents is not 
part of the cause because the rate of consanguinity and inbreeding coefficients are 
very small in Finland. Instead, remote consanguinities are important factors in FDH 
(Norio 2003a). 
Early and late settlement areas in Finland are often mentioned when discussing 
disorders belonging to FDH. The early population in Finland was mostly 
THL — Research The Molecular Basis of  
Hydrolethalus Syndrome
2 Review of the Literature
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concentrated in the coastal region whereas the late settlement area in the inland was 
effectively populated starting in the 1500s mainly from the Savo area, the national 
movement strongly influenced by King Gustavus Vasa (Norio 2003a). A map 
describing the areas of early and late settlement is presented in Figure 3 in section 
2.3.1 (page 23). 
There are different kinds of spreading patterns of disorders belonging to FDH and 
thus, the autosomally recessively inherited disorders have been divided into five 
groups (Norio 2003a). In the largest group of 16 disorders (for example congenital 
lactase deficiency), most of the birthplaces of the affecteds´ grandparents are located 
at the late settlement area (Figure 1A). This kind of a spreading pattern suggests that 
the disease mutation had appeared in the Finnish population before the population 
started to spread to late settlement area. The second group of distribution includes 
the six most common disorders (for example congenital nephrosis of the Finnish 
type, CNF) and they have been determined to have spread to most parts of the 
country (Figure 1B). Based on this fact, these mutations are probably the oldest 
FDH mutations in the population. The third group is formed only by diastrophic 
dysplasia and the Meckel syndrome. They are mostly distributed in the western part 
of the country and the distribution follows the population density in Finland. These 
disorders are seen worldwide and there is a possibility that these mutations have 
been brought to Finland with the western Indo-European immigrants (Norio 2003b). 
The fourth group comprised of northern epilepsy and the Finnish variant of Jansky-
Bielschowsky disease are strictly regional, thus suggesting that their mutation is 
very young (Figure 1C). The remaining four disorders (for example RAPADILINO 
syndrome) are grouped as their own entity because their maps are atypical with no 
similarities with the other four groups. Also, only a small number of families are 
affected by these disorders. 
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Figure 1. Distribution patterns of congenital lactase deficiency (A), CNF (B) and northern 
epilepsy (C). Modified from Norio 2003c. 
2.2 Identification of disease genes 
The important step in the era of DNA research was made when the helical structure 
of DNA was first published in the 1950´s (Watson and Crick 1953). Identification of 
disease genes has experienced an enormous leap in the recent years due to the 
development of new study methods. The human genome project was initiated in 
1990 in order to determine the nucleotide sequence of the human genome and at the 
same time, identify the genes that this sequence contains. The initial draft version of 
the genome was published by the International Human Genome Sequencing 
Consortium (Lander et al. 2001) simultaneously with a private company Celera 
Genomics (Venter et al. 2001). The nearly complete version of the sequence was 
published a couple of years later by the International Human Genome Sequencing 
Consortium (IHGSC 2004). 
2.2.1 Positional cloning 
When searching for the disease-causing gene in a population, usually there is no 
information of the possible causative gene readily available. A method called 
positional cloning has been widely used in these kinds of situations in the research 
of monogenic diseases (Collins 1992, 1995). A work-flow for positional cloning is 
THL — Research The Molecular Basis of  
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presented in Figure 2. In this method, disease gene identification is based on its 
genomic location instead of its known function. When studying isolated populations, 
there is a great possibility that a common genetic factor may be found behind the 
same phenotype shared with the patients. In order to achieve reliable results, the 
phenotypic criteria for the disease should be strict enough and the diagnoses should 
be done as accurately as possible. 
 
 
Figure 2. Main steps of the positional cloning method. 
 
In the positional cloning method, DNA material is first collected from the affecteds, 
siblings and parents as widely as possible and the samples are genotyped using a 
genome-wide marker genotyping (see section 2.2.2). After the genotyping step, 
linkage analysis (see section 2.2.2) is performed to find a genomic region where the 
possible genetic defect is situated. 
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2.2.2 Genetic mapping 
Microsatellites and SNPs as genetic markers 
The most used methods for genotyping are based on the microsatellite markers 
(Dubovsky et al. 1995) and single nucleotide polymorphisms (SNPs) (Frazer et al. 
2007), which are naturally occurring variations in the genome between individuals. 
Microsatellites are stretches of DNA where a certain nucleotide combination most 
often comprised of 2-4 nucleotides is repeated several times. The best microsatellite 
markers are the ones which have several different alleles in the population. 
Microsatellites are spread over the human genome at the average of once in every 2 
kilobases (kb) (Lander et al. 2001). Initial screening of the genome is usually done 
using these variable markers, but additional markers are often needed for further 
studies. SNPs are less polymorphic when compared to microsatellites because they 
usually contain only two alleles, but lower mutation rates make them also more 
stable (Gray et al. 2000). The appearance of SNPs is quite dense, approximately 10 
million of them can be found in the human genome. The microsatellite scan was a 
widely used technique earlier, but nowadays SNP scans are more commonly used 
since this method has proven to be more efficient with the developed and the time-
saving array-based technique. 
 
Linkage and haplotype analyses 
Before it is possible to find the specific disease-causing gene, the genomic candidate 
region has to be identified by a statistical approach called linkage analysis 
(Dubovsky et al. 1995). The purpose of the analysis is to find a specific 
chromosomal region for a disease locus using polymorphic markers. The closer a 
marker locus is to a disease locus the more rarely recombinations are able to 
separate these two loci from each other. Thus, two loci are said to be genetically 
linked. In the linkage analysis method, the proportion of recombinations observed is 
used as a measure of genetic distance between two loci. To determine possible 
linkage, the recombination fraction between the two loci must be resolved. Also, it 
has to be determined whether the recombination fraction is significantly different 
from 0.5, the value that is expected with no linkage (Teare and Barrett 2005). 
Depending on the data available, there are different forms of linkage analysis that 
can be used, including two-point, multipoint, parametric and non-parametric 
analyses. 
When the initial identification of the candidate region is made, regions are often 
found to be broad and to contain a large number of genes. Thus, haplotype analyses 
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and linkage disequilibrium (LD) studies are used for fine mapping in order to make 
the critical region as short as possible. Haplotypes are combinations of alleles of 
adjacent markers in the genome that tend to be transmitted together from one 
generation to the next. Haplotypes get shorter with time because of the 
recombinations between homologous chromosomes in meiosis. In general, the older 
the formed haplotype is, the shorter is its length. Haplotypes become shorter rapidly 
if a phenomenon called recombination hot spot is located at the genomic region 
(Nishant and Rao 2006). LD in turn refers to the non-random association of 
particular alleles at loci close to each other that occur more frequently than would be 
expected. When studying monogenic diseases in the isolated population such as 
Finns, genomic areas where the affecteds share the same haplotype are often 
searched for. This is applicable when it can be assumed that the disorder is caused 
by one ancestral founder mutation. In the course of identifying the disease genes, it 
has been noted that in the Finnish population, the size of the shared region can vary 
significantly between different syndromes. The reason for this can be for example 
the age of the mutation (Peltonen et al. 1999). 
2.2.3 Mutation analysis 
After the genetic mapping procedure, individual candidate genes in the critical 
region have to be tested to determine if they are causing the disease phenotype or 
not. Nowadays, mutation screening to find the disease-causing DNA change is 
commonly performed by the direct sequencing method. If the function of the genes 
in the critical region is known and their function can be linked to the disease, the 
best candidate genes for the sequencing can be easily found. But even if information 
from all genes is nowadays easy to find using different databases, the screening 
project can still be complicated and might need a lot of time to be successful. 
When screening for mutations in the DNA sequence, several different kinds of them 
can be found. In a point mutation, one of the nucleotides in the sequence is changed 
to another. This change can lead to either nonsense, missense or splice site mutation. 
The nonsense mutation causes a premature stop codon in the coding region of the 
gene, this causing either protein degradation or a truncated protein. In a missense 
mutation, one of the amino acids in the polypeptide is changed to an other, this 
change possibly affecting the structure and/or function of the protein. In splicing 
mutation, mutations affecting the consensus sequences at splice donor or acceptor 
sites or at splice branch sites may make them less effective and eliminate the 
splicing partially or completely. It is also possible that nucleotide change might 
introduce a new splice site (Cartegni et al. 2002). A point mutation can also be 
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translationally silent, thus not affecting the amino acid composition of the produced 
polypeptide. 
Other types of mutations include deletions, insertions and duplications that can 
range from one nucleotide to large genomic segments. If deletions and insertions do 
not occur in the group of three nucleotides or multiples of this, they cause frameshift 
mutations leading to a premature stop codon or defective splicing. In an inversion 
mutation, an entire section of DNA is reversed. A small inversion may involve only 
a few bases in a gene, while longer inversions can include large regions of a 
chromosome containing several genes. Translocation in turn is a type of unnatural 
genome rearrangement, where two non-homologous chromosomes exchange parts 
of their arms and this can lead, for example, to the disruption of a gene. 
To confirm a particular change in DNA to be disease-causing, several criteria have 
to be met. Mutation screening in patients has to reveal at least one change in the 
DNA sequence that segregate with the disease in the patients´ families and this 
segregation has to be consistent with the proposed mode of inheritance. Possible 
disease-causing DNA variants are also important to differentiate from neutral 
polymorphisms. For this, a large enough number of unaffected individuals 
representing the respective population have to be screened. Also, functional analyses 
are usually needed to perform to determine the role of the sequence variation in the 
cellular and tissue levels (see below). 
 
Functional analyses 
Numerous functional analyses are possible to be performed to study the nature of the 
DNA variants and their consequences. In silico, this can be made by analyzing the 
gene and/or the protein sequence by exploring various internet databases and using 
computer-assisted bioinformatic sequence analysis tools. Analyses can be made for 
instance to predict the physical and chemical characteristics of the proteins as well as 
to search orthologies with other species. One should bear in mind, however, that these 
programs might give contradictory results and that the predictions are based solely on 
the sequence provided in the analysis. Thus, further laboratory research is usually 
needed to confirm the proposed function. Just to mention a few, genomewide gene 
expression profiling using microarray-based techniques, analysis of spatial and 
temporal gene expression patterns by reverse transcription polymerase chain reaction 
(RT-PCR) analysis, determination of the intracellular localization of the protein using 
an overexpression system in cell line cultures and immunoblotting are methods that 
can be used in gene and protein characterization. A laborous procedure for creating an 
animal model based on the sequence variation in question can at best give definitive 
verification for the pathogenic role of the altered gene form. 
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2.3 Hydrolethalus syndrome 
2.3.1 History 
Hydrolethalus syndrome (HLS, MIM 236680) is a rare lethal malformation 
syndrome of the fetal stage characterized by several developmental malformations. 
This syndrome is enriched in the Finnish population and is part of the Finnish 
disease heritage. HLS has an autosomal recessive heritability with an incidence of at 
least 1:20,000 in Finland. HLS was first described by Riitta Salonen and her 
colleagues in 1981 during a nationwide study of Meckel syndrome (MIM 249000). 
Both of these syndromes are characterized by severe central nervous system (CNS) 
malformations as well as polydactyly (ie. extra fingers and toes) as their main 
features. Although these two syndromes share similar defects, there are also clear 
differences. For example, in HLS there have not been cases with the cysts in the 
kidneys or other parenchymatous organs, this being perhaps the single most 
characteristic anomaly of Meckel syndrome (Salonen et al. 1981). In addition, in 
HLS, the frequent finding is hydrocephalus, that is an uncharacteristic feature in 
Meckel syndrome. 
Figure 3 shows the areas of early and late settlement areas as well as the distribution 
of the birthplaces of the great grandparents of Finnish HLS cases. This kind of map 
is typical for several other diseases of FDH, too (Norio 2003a). It has been estimated 
that the HLS mutation was most probably introduced to the Finnish population about 
30-40 generations ago (Visapää et al. 1999). 
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Figure 3. Distribution pattern of hydrolethalus syndrome in Finland. The line represents the 
division between early and late settlement areas, early settlement concentrating in the coastal 
area and late settlement on the mainland. Modified from Visapää et al. 1999 and Norio 
2003a. 
 
2.3.2 Clinical picture 
HLS is characterized by several developmental malformations of the CNS and many 
other organs. Some of the malformations are very frequent but some of them are not 
seen in every case. The phenotypic appearance of the syndrome can thus be decribed 
as a wide spectrum of features. A large hydrocephalus, micrognathia (small 
mandible) and polydactyly can be named as typical manifestations of HLS. The 
main features and their observed frequencies in HLS cases (Salonen and Herva 
1990) have been listed in Table 1. Most prominent clinical features are shown in 
figure 4 on page 26. 
THL — Research The Molecular Basis of  
Hydrolethalus Syndrome
2 Review of the Literature
 24 
Table 1. Main clinical features and percentage of the observed frequencies in 56 individuals 
with hydrolethalus syndrome. Modified from Salonen and Herva 1990. 
Clinical feature Percentage 
Micrognathia 100 
Polyhydramnios 91 
Anomalous nose 89 
Small / deep set eyes 87 
Hydrocephalus 85 
Gestational age < 38 weeks 78 
Polydactyly 78 
Occipital bone defect 75 
Stillborn 73 
Anomalous / low set ears 64 
Defective lobulation of the lungs 62 
Abnormal genitalia 59 
Abnormal larynx / trachea 58 
Cleft lip / palate 52 
Club feet 48 
Congenital heart disease 46 
Short limbs 20 
Urinary tract anomalies 16 
 
 
Polyhydramnios is one of the typical HLS features with the amount of the amniotic 
fluid found to be up to 8 litres (Salonen et al. 1981) while normally, the amount of 
the amniotic fluid varies from 0.5 to 1 litre (Sariola et al. 2003). In the past, many of 
the HLS fetuses were stillborn, but some of the liveborn infants lived from a few 
minutes to a few days (R. Herva, personal communication; (Salonen and Herva 
1990). HLS can nowadays be diagnosed already in utero by ultrasound scan 
(Hartikainen-Sorri et al. 1983) already at the end of the first trimester of pregnancy 
(Ämmälä and Salonen 1995). Due to the severe malformations most of the families 
decide to terminate the pregnancy. 
The most frequent CNS abnormality in HLS is a large hydrocephalus, with an 
extreme case of 2100 ml of fluid reported (Salonen et al. 1981). A few cases with 
anencephaly have also been seen (Salonen and Herva 1990; Salonen et al. 1981). No 
cases with holoprosencephaly with only one brain hemisphere have been described. 
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In the typical cases with hydrocephalus, the hemispheres are separated and they lie 
at the bottom of the skull. The upper midline structures, including the corpus 
callosum and septum pellucidum, are absent. A special kind of occipitoschisis is 
found in many times, forming a cleft in the base of the skull in the midline of the 
occipital bone and forming a keyhole-shaped opening. In some cases the pituitary or 
olfactory nerves are absent. Frequently, the gyration of the brain is grossly 
abnormal. It has been suggested that a rapidly expanding hydrocephalus may cause 
the defects in the craniofacial development (Krassikoff et al. 1987). 
Craniofacially, the most frequent finding is micrognathia, i.e. a small, sometimes 
rudimentary, mandible. Cleft palate or lip has also been reported as well as 
malformations in the tongue, nose, ears and eyes (Salonen and Herva 1990; Salonen 
et al. 1981). In the eyes, a coboloma and hypoplasia of the optic nerve has been 
reported (Kivelä et al. 1996). In the limbs, polydactyly is frequently documented. 
Polydactyly, which means extra toes and/or fingers, is usually postaxial in the hands 
and preaxial in the feet. Hallux duplex, a duplicated big toe, is a hallmark feature in 
the feet. Also other abnormalities in the limbs, for example club-foot-like deformity 
and abnormally short arms and legs have been found (Herva and Seppänen 1984; 
Salonen et al. 1981). 
About half of the reported cases have had a congenital heart defect (Salonen and 
Herva 1990), the main finding being a large ventricular septal defect. Also 
respiratory organs, including the larynx and the trachea, have sometimes been 
reported to be abnormal. In some cases, the lobulation of the lungs has been 
incomplete or completely absent. There have been cases with mild abnormalities of 
the genitalia, but the sex has always been distinguishable (Salonen et al. 1981). 
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Figure 4. An HLS fetus of 19th gestation week with some of the most prominent clinical 
features shown. 
There have been several reports about non-Finnish cases having overlapping 
features with the Finnish HLS cases, see e.g. (Adetoro et al. 1984; Anyane-Yeboa et 
al. 1987; Aughton and Cassidy 1987; Bachman et al. 1990; Chan et al. 2004; de 
Ravel et al. 1999; Krassikoff et al. 1987; Morava et al. 1996; Rakheja et al. 2004; 
Shotelersuk et al. 2001; Toriello and Bauserman 1985). Some of the cases were 
either stillborn (Rakheja et al. 2004) or were detected by ultrasound and because of 
the severe findings, the pregnancy was terminated (Bachman et al. 1990; Chan et al. 
2004). Also a “milder” form of HLS has been reported. For example, Shotelersuk et 
al. (2001) reported a case that survived for over a month and Aughton and Cassidy 
(1987) and de Ravel et al. (1999) reported cases that lived for several months. It has 
been suggested that the less severe cases are also true HLS cases and that the 
underlying cause of the inconsistency between severe and mild cases is allelic 
variability (de Ravel et al. 1999; Shotelersuk et al. 2001). Also, Pryde et al. 
suggested allelic variability for HLS between Finnish and foreign cases (Pryde et al. 
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1993). In addition, Christensen et al. proposed that acrocallosal syndrome and HLS 
could be allelic syndromes (Christensen et al. 2000). 
2.3.3 Genetics 
Visapää and her colleagues assigned the hydrolethalus syndrome locus to 
chromosome 11q23-25 in Finnish families (Visapää et al. 1999). The initial genome 
scan study was performed using DNA material from 15 affected individuals and 20 
healthy family members from eight HLS families. The critical locus was first 
assigned to an 8.5 cM interval by linkage analysis and the locus was finally further 
restricted to a 0.5-1 cM region using linkage disequilibrium and haplotype analyses. 
In addition, seven HLS cases all from different families and the parents of four of 
these families were included in the linkage disequilibrium studies. The parents of 
HLS cases were generally non-consanguineous. Six parents were found to be 
related, the earliest identified link between ancestors being seven generations old 
and the most recent link was found in the family where the parents were first 
cousins. Genealogical studies from 40 families affected by HLS revealed that HLS 
does not have any specific regional clustering in Finland and that the majority of the 
great-grandparents´ birthplaces are situated in the late settlement area (Figure 3). 
According to the genealogical studies, one major founding mutation for HLS could 
be predicted (Visapää et al. 1999), as in several other Finnish syndromes (Peltonen 
et al. 1995). To assure the strict qualification of HLS cases in this study, all the 
diagnoses were confirmed by one clinician and all the affecteds in the families 
represented very typical cases of HLS with the prominent features of the syndrome 
(Visapää et al. 1999). 
2.3.4 Differential diagnostics 
There are some syndromes and conditions that have a partially overlapping spectrum 
of features with HLS but there are also some fundamental differences that separate 
these syndromes from each other. Since there can be a quite significant phenotypic 
spectrum inside multiple developmental anomaly syndromes, it can sometimes be 
difficult to categorize affected patients to some distinct syndrome. The difficulties of 
differential diagnostics in multiple severe malformation syndromes containing also 
midline development disturbances have been discussed in several publications, see 
e.g. (Hennekam et al. 1991; Pryde et al. 1993). 
In addition to Meckel syndrome, from which HLS was initially separated, other 
resembling syndromes include for example orofaciodigital syndrome (OFD) type IV 
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(Mohr-Majewski or Baraitser-Burn syndrome; MIM 258860) (Toriello et al. 1997), 
OFD type VI (Varadi-Papp syndrome, MIM 277170) (Doss et al. 1998; Varadi et al. 
1980), and acrocallosal syndrome (ACLS, MIM 200990) (Koenig et al. 2002; 
Nelson and Thomson 1982). In OFD type IV, symptoms include brain 
abnormalities, minor facial and oral anomalies and variable digital defects such as 
polydactyly. OFD type IV is suggested to represent genetic heterogeneity among the 
patients (Toriello et al. 1997). OFD type VI is distinguished from other oral-facial-
digital syndromes by metacarpal abnormalities with central polydactyly and by 
cerebellar abnormalities (Doss et al. 1998). ACLS is characterized by agenesis of the 
corpus callosum, minor craniofacial anomalies, pre- and postaxial polydactyly and 
psychomotor retardation (Koenig et al. 2002). In addition to these syndromes, 
Pallister-Hall syndrome (PHS, MIM 146510) and Smith-Lemli-Opitz syndrome 
(SLOS, MIM 270400) also resemble HLS. These two syndromes are discussed in 
more detail below. 
In 1995, Verloes used a mathematical approach to compare syndromes with 
complex phenotype and with partially overlapping symptoms by ranking the 
phenotypic features and using statistical methods to analyze the outcome (Verloes 
1995). For this approach, Verloes used a term “numerical syndromology”. The 
syndromes used in the comparisons included hydrolethalus, Smith-Lemli-Opitz, 
Pallister-Hall, OFD type VI and holoprosencephaly-polydactyly syndromes. He 
concluded that these syndromes are clearly independent phenotypic entities. Still, as 
the phenotypic spectrum of these syndromes can vary significantly, the diagnosis of 
some uncertain cases can be quite difficult. 
 
Pallister-Hall syndrome 
PHS is a disorder with the most resemblance to HLS. PHS was first described in the 
1980s with several malformations (Clarren et al. 1980; Hall et al. 1980). As in HLS, 
also in PHS malformation of the brain can be seen, the hallmark feature being 
hypothalamic hamartoblastomas. Other frequently occurring features are 
craniofacial anomalies in general as well as micrognathia, polydactyly, defective 
lobation of the lungs, congenital heart defects and cleft lip or palate (Hall et al. 
1980). Skeletal malformations have also been reported (Roscioli et al. 2005). Most 
of these features can be seen in HLS fetuses, too. In contrast, for example an 
imperforate anus and renal abnormalities are the features often reported from PHS 
patients but not seen in HLS. Life expectancy is also higher in PHS than in HLS. 
The symptoms in PHS can vary from very mild to severe, the patients´ life span 
varying from few months to adulthood. The variance in the phenotypic spectrum is 
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true for HLS cases, too, but the symptoms are more severe in HLS generally leading 
to death at the very early stages of life. 
The causative gene for PHS is GLI3 at chromosome 7p13, the disease-causing 
mutations being nonsense and splicing mutations (Johnston et al. 2005; Kang et al. 
1997a; Kang et al. 1997b). The mode of inheritance in PHS is autosomal dominant. 
GLI3 is homologous to the Drosophila cubitus interruptus (ci) gene product (Ci) and 
acts as a transcription factor in the Sonic hedgehog (SHH) signaling pathway. This 
pathway contributes to several essential cellular events during fetal development, 
including development of the neural tube, craniofacial structures, the lung and the 
limb, among others (Biesecker 2006). Mutations in GLI3 also cause Greig 
cephalopolysyndactyly syndrome (GCPS, MIM 175700) and thus, PHS and GCPS 
are allelic syndromes. However, the mutations causing GCPS are partially of 
different kinds (deletions, chromosomal translocations) and located in a different 
region than in PHS (Johnston et al. 2005). Johnston et al. also suggested that a 
truncated functional repressor protein of GLI3 causes PHS, whereas 
haploinsufficiency of GLI3 would in turn be the cause for GCPS. In addition to PHS 
and GCPS, also in acrocallosal syndrome at least one case with a mutation in the 
GLI3 gene has been reported (Elson et al. 2002). As GLI3 has been excluded as the 
site of mutation in some cases of ACLS, the authors suggested that ACLS may be a 
heterogeneous group of disorders where the phenotype, in some cases, results from a 
mutation in GLI3 and represents a severe, allelic form of GCPS (Elson et al. 2002). 
 
Smith-Lemli-Opitz syndrome 
SLOS is an autosomally recessively inherited congenital syndrome with multiple 
developmental abnormalities first reported in 1964 (Smith et al. 1964). SLOS has a 
wide spectrum of phenotypic features that vary from mild symptoms with learning 
and behavioral problems to a lethal malformation syndrome (Hennekam 2005; 
Porter 2008). Prominent features of the syndrome include microcephaly, 
micrognathia, growth retardation, holoprosencephaly, ptosis, cleft palate and 
polydactyly. Because of the variable phenotype, division into a mild (SLOS I) and 
severe (SLOS II) forms of the syndrome have been suggested (Curry et al. 1987).  
SLOS is caused by mutations in the sterol 7-dehydrocholesterol reductase gene 
(DHCR7), which is the last step in the cholesterol metabolism pathway. Over 130 
different mutations of DHCR7 have been so far identified in SLOS patients (Correa-
Cerro and Porter 2005; Porter 2008). The mutations cause increased serum levels of 
7-dehydrocholesterol and decreased serum levels of cholesterol in patients (Irons et 
al. 1993; Tint et al. 1994). The relation between the genotype and severity of the 
symptoms in SLOS is controversial, since reports demonstrating both quite poor 
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(Correa-Cerro et al. 2005) and quite good (Witsch-Baumgartner et al. 2000) 
genotype-phenotype correlation in patients have been published. SLOS diagnosis 
can nowadays be made prenatally by measuring 7-dehydrocholeserol levels in 
amniotic fluid or chorionic villus samples or alternatively by direct mutation 
analysis of DHCR7 (Waye et al. 2007). The possibility for non-invasive diagnosis 
by maternal urinary steroid level measurement has also been suggested (Jezela-
Stanek et al. 2006). Based on genetic studies, SLOS is very rare in Finland (Witsch-
Baumgartner et al. 2008). 
2.4 Fetal development 
2.4.1 General aspects 
Human fetal development from a single cell to a living organism is a complex and 
remarkable phenomenon, guided both by genes and the environment. Fetal 
development can be divided into three main stages called blastogenesis, 
organogenesis and fetogenesis. Blastogenesis is the interval of the first four weeks 
after fertilization, until the neural tube closure. Organogenesis is the stage from the 
end of blastogenesis to nine weeks of gestation. This is the main stage of organ 
development. Fetogenesis lasts from week nine until birth, the stage when the fetus 
has the major organ patterning mainly developed and when the fetus grows in size. 
Growth of the fetus is fastest in the early stages of fetogenesis (Carlson 2004; 
Sariola et al. 2003). 
Organs start to develop at an early stage of fetal development. For example the 
brain, eye, heart and gastrointestinal tract start their development in a three week old 
embryo, the spinal cord and auditory system at three or four weeks, the olfactory, 
renal and limbs at 4-5 weeks and the respiratory tract and genitalia at five weeks. 
Based on their complexity, organs take different times to complete their 
development. For example, the heart is formed at 6 weeks, the face and limbs at 
eight weeks whereas the structural development of the brain continues until 28 
weeks. Organs of course grow in size and mature further in utero and also 
postnatally after their structural development is completed in the fetal period 
(Carlson 2004; Sariola et al. 2003). 
Inductive signaling between tissues is a critical regulator of the development of 
different organs. For example in the developmental processes of the lung and the 
kidneys, interaction between the mesenchyme and the epithelium of the tissue is 
critical for appropriate formation of the organ (Sariola et al. 2003). It is typical of 
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mesenchyme-epithelium signaling that both tissues participate actively in the 
signaling events. Signaling continues through the whole organ development and it is 
mediated through soluble molecules. In order to be able to react correctly to every 
signal, cells must have the right receptors in their surface to receive the messages. 
Also, molecules for intracellular signal transduction and target gene expression 
machinery must be available. 
2.4.2 Key molecules and signaling pathways 
Normal human development requires the precise functioning and coordination of 
many complex pathways and signaling cascades. Interestingly, a large proportion of 
the genes regulating the fetal development are basically the same in different groups 
of animals. These key molecules are used not only in the early embryonal stage but 
later in the organ development, as well. Studies of these key molecules in relatively 
simple organisms such as Drosophila melanogaster (fruit fly) and Caenorhabditis 
elegans (ground worm) have given us a massive amount of essential knowledge 
about the molecular cascades required during the developmental processes. Many 
signals that are essential in the development of vertebrates are the members of the 
following four families: Hedgehog (HH), Wingless (WNT), fibroblast growth factor 
(FGF) and transforming growth factor beta (TGF) (Carlson 2004; Sariola et al. 
2003). They can be found in every organ of the developing fetus. It is mostly quite 
hard to unravel the meaning of a single molecular signal during development since 
the same signals are used constantly and since the cells express and also receive 
several signals simultaneously. In addition, different signal pathways cross each 
other and also affect each other. 
In the early development, some of these important molecules are distributed from 
certain signaling centrals (such as the isthmic organizer and the zone of polarizing 
activity), which are temporary structures that produce many different kinds of 
signaling molecules simultaneously and thus affect the formation and differentiation 
of the surrounding tissues. One crucial group of molecules are the ones that transmit 
the signaling between cells in the body. This usually leads to activation of the 
transcription factors that in turn affect the genes that they are targeted to. 
2.4.3 Development of the central nervous system 
Nervous system development can be divided into the following eight main 
subsequent stages: 1) induction of neuronal tissue in the ectoderm and patterning, 2) 
establishment of neuroblasts and their migration, 3) differentiation of neuronal cell 
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types, 4) axonal guidance, 5) establishment of synaptic connections, 6) regulation of 
the amount of neuronal cells by apoptosis, 7) further arrangement of synaptic 
connections, and 8) arrangement of synaptic connections by their activity and 
usefulness, i.e. synaptic plasticity (Sariola et al. 2003). The most important gene 
groups of the developmental toolbox used for CNS development include in large 
part the same groups as mentioned earlier, such as Hedgehog (HH), Wingless 
(WNT), fibroblast growth factor (FGF) and the Notch families as well as bone 
morphogenetic proteins, a subclass of TGF superfamily, see e.g. (Bertrand and 
Dahmane 2006; Ford-Perriss et al. 2001; Fuccillo et al. 2006; Mehler et al. 1997; 
Monuki 2007). 
Development of CNS starts at the very beginning of embryonic stage when a group of 
ectodermal cells are induced by the underlying ectoderm (notochord). This event is 
called primary induction. Induction is a phenomenon where a group of cells coordinate 
adjacent cells changing their behavior and therefore making them change in some 
way. Induced neuroepithelial cells then form a thickened neural plate overlying the 
notochord. The neural plate develops further from the neural groove to the closed 
neural tube, an event that is assisted by several essential developmental molecules and 
their gradients (see above). Neural tube closure is complete already on the 28th day 
after fertilization (Sadler 2005). The brain itself is developed from the dilations 
processed by the cephalic portion of the neural tube, formed by the migrating neurons 
that establish different laminar compartments (Bystron et al. 2008). 
Cortical lamination is a phenomenon where laminar compartments of the developing 
brain cerebral cortex with their own, special cell types are formed. Three main types 
of precursor cells in the early stages of the cortex development have been identified: 
radial glial cells and short neural precursors in the ventricular zone and intermediate 
progenitor cells in the subventricular zone (Dehay and Kennedy 2007). The 
ventricular zone cells are involved in the generation of lower layer neurons, while 
the cells situated in the subventricular zone generate upper layer neurons (Dehay and 
Kennedy 2007). Radial glia produced in the ventricular zone provide a ladder 
system to assist the neurons in their way to the correct compartment in the cortex 
(Campbell and Götz 2002). However, different neuronal types have been found to 
use distinct modes of migration in the developing cortex. The early-generated 
neurons use somal translocation, and pyramidal cells predominantly use glia-guided 
locomotion. A third mode of migration is used by cortical interneurons. They 
migrate tangentially into the cortex, then seek the ventricular zone before moving 
radially to take up their positions in the cortical anlage (Nadarajah and Parnavelas 
2002). The mature cortex contains several different layers (Figure 5). The 
heterogeneous and confusing nomenclature used to describe the developing CNS led 
a special committee to clarify the sequence of events taking place during cortical 
THL — Research The Molecular Basis of  
Hydrolethalus Syndrome
2 Review of the Literature
 33 
development and this also set the nomenclature used for different compartments 
(Bystron et al. 2008). Recent studies have however increased our knowledge of new 
cell types, patterns of genetic expression and additional cellular compartments and 
thus, some revisions for the committee nomenclature have been suggested (Bystron 
et al. 2008).   
 
 
Figure 5. During the cortical lamination, several distinct cellular zones are formed. Modified 
from (Nadarajah and Parnavelas 2002). VZ, ventricular zone, IZ, intermediate zone, SP, 
subplate, CP, cortical plate, MZ, marginal zone. 
 
The central nervous system contains more cell types than any other organ in the 
human body. The overall number of these cells is great, about 1011 neurons and 1012 
glial cells (Diaz 2006). Although the basics of the cell types and their function in the 
brain is currently known, there still remains the possibility that all of the possible 
cell types of the brain are not yet identified (Diaz 2006).  
The main classes of the cell types in CNS include neurons and glial cells. Neurons 
and glial cells can be further divided into many subgroups. Neurons can be classified 
by their structure and function or, for example, based on which neurotransmitter 
they produce. In addition to neurons, much of the total volume of the brain is made 
up of cells that support neurons in various ways but which do not carry information 
themselves. The collective name for these support cells is glial cells and they can be 
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divided into the groups of oligodendrocytes, astrocytes, and microglia. The word 
“glia” comes from the Greek word for glue. Glial cells have several different 
functions in the brain. In addition to support, their functions include transporting 
nutrients to nerve cells, cleaning up debris and digesting parts of dead neurons. Glial 
cells also provide insulation to neurons through the production of myelin. These 
cells are called oligodendrocytes in the CNS. For a general review of glial cells, see 
e.g. (Ndubaku and de Bellard 2008). Radial glial cells have an important role in key 
developmental processes of the CNS as precursors during neurogenesis and as 
mentioned earlier, in the lamination events of cerebral cortex (Campbell and Götz 
2002) (Figure 6). Glial cells produced later in CNS development are mainly 
astrocytes: type 1 in the white matter and type 2 in the grey matter. Microglial cells 
in the CNS are resident immune cells that regulate and participate in immune 
responses in CNS tissue (Garden and Möller 2006). They also appear to play an 
important role during the normal function of the mature nervous system. One special 
glial cell type is also ependymal cells which give rise to the choroid plexus, a 
structure located inside the brain ventricles that produces cerebrospinal fluid (CSF) 
(Sariola et al. 2003). 
 
 
Figure 6. A radial glial cell and a migrating neuron. Modified from 
www.dls.ym.edu.tw/lesson3/nerv1.htm 
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2.4.4 Congenital malformations and malformation syndromes 
Approximately 2-3% of the living newborns can be diagnosed with at least one 
congenital malformation. These malformations can range from very mild symptoms 
to very complex and gross anatomical abnormalities. Only about half of the 
malformations can be explained by genetic or environmental factors. Estimations of 
genetic causes cover about 20-30% of the cases from which about 3-10% are due to 
chromosomal aberrations and 4-8% are of monogenic background. Environmental 
factors such as teratogens explain roughly 7 to 10% and multifactorial causes 20 to 
25% of the malformations (Carlson 2004; Sariola et al. 2003). 
The period for most likely susceptibility to abnormal development caused by 
external factors such as teratogens (e.g. alcohol, drugs, ionizing radiation) is 
between three and eight weeks of gestation. As mentioned earlier, this is the period 
when most of the body regions and major organs begin to develop. Developmental 
abnormalities arising after eight weeks are likely to affect the function of the organ 
or interaction between them (for example mental retardation) or be related to the 
growth of already formed body parts. It should be noted, though, that different 
external factors can influence the fetus in the different developmental stages. Also, 
different organs have different periods of susceptibility during embryonic 
development and moreover, the most complex organs such as the brain, show 
prolonged periods during which they have a high probability of being influenced by 
these agents (Carlson 2004). 
Disorders caused by a genetic factor are naturally inborn, but the onset of the 
recognizable symptoms can vary significantly from fetal period to adulthood. If we 
use monogenic disorders of Finnish disease heritage as examples, hydrolethalus, 
Meckel syndrome and lethal congenital contracture syndrome (LCCS) for instance 
lead to stillbirth or death already in utero or shortly after birth whereas the onset in 
neuronal ceroid lipofuscinoses (NCLs) can vary from infancy to adulthood 
depending on the form of the disease (Norio 2003c). In PLOSL (polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy), the patients 
are usually symptomless until 20 years of age (Norio 2003c). 
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3 AIMS OF THE STUDY 
 
The aims of this study were the following: 
 
• To identify the gene and the mutation(s) causing HLS (I). 
 
• To define the general pathological and detailed neuropathological status 
associated with a defect in the HYLS1 gene (II). 
 
• To characterize the function of the HYLS1 protein and to gain insight into 
the pathogenesis of HLS (I, III). 
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4 SUBJECTS, MATERIALS AND METHODS 
4.1 Families, DNA and tissue samples 
The study consisted altogether of 54 Finnish families with 73 suspected HLS cases. 
The HLS diagnosis was based on ultrasound and/or autopsy findings. We had DNA 
samples from all the cases and also tissue samples from some of the cases. We also 
had an opportunity to study 11 foreign families with at least one individual 
diagnosed or suspected to be an HLS case. In five of these families, only the 
affected´s sample was available. In addition, we had an opportunity to use DNA and 
tissue samples from fetal control cases aborted for social reasons. 
4.2 Ethical aspects 
Studies on DNA and tissues of HLS cases and their family members as well as fetal 
control material were approved by the Ethical Committees of the Joint Authority for 
the Hospital District of Helsinki and Uusimaa. 
4.3 Methods presented in original publications 
The methods used in the present study are listed below and described in detail in the 
original publications (Roman numerals I-III). 
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Method Original publication 
Antibody production I 
Bioinformatic analyses I, II 
Cell cultures, primary and stable cell lines I, III 
Cell transfections I, III 
Cloning of cDNA I 
Confocal microscopy I 
DNA extraction I, II 
DNA sequencing I, II 
Flow cytometry III 
Fluorescence microscopy I, II, III 
Genotyping I 
Haplotype and LD analysis I 
In situ hybridization I 
Microarray analysis III 
Light microscopy I, II 
Lipid extraction from tissue III 
Polymerase chain reaction (PCR) I, II 
Production of transgenic HYLS1 Drosophila 
melanogaster lines I 
Proliferation assay III 
Protein detection by immunofluorescence staining I, III 
Protein detection by immunohistochemical staining II 
Protein detection by western blot analysis I 
Pulse-chase analysis I 
Reverse-transcriptase PCR I 
RNA extraction I, III 
Transactivation assay III 
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4.4 Methods used in unpublished studies 
 
Sumoylation assay (section 5.1.3) 
For studying possible interaction between HYLS1 and SUMO-1 (small ubiquitin-
like modifier 1), the overexpression cell model was used. COS-1 cells were seeded 
onto 10 cm Petri dishes at 1.8 x 106 cells per dish and transfected the next day with 
either wt or mutant human HYLS1 construct alone or together with His-tagged 
SUMO-1 construct. In addition, HYLS1, SUMO-1 and either FLAG-tagged PIAS1 
construct or FLAG-tagged ARIP3 construct were transfected simultaneously. 
Transfections were performed using the Fugene HD transfection reagent according 
the manufacturer´s instructions. The cells were collected 48 h after transfections in 
phosphate buffer solution (PBS) containing 20 mM N-ethylmaleimide (NEM). Cell 
extracts were prepared in buffer containing 2% SDS, 10 mM Tris–HCl pH 8.0, and 
150 mM NaCl, then incubated for 10 min at 95 °C, and diluted 1:9 in buffer 
containing 1× TBS, 10 mM NEM and 1% Triton X-100. The cell lysate was 
homogenized using a syringe and needle and centrifuged at 16,000 × g for 20 min at 
4 °C. A total of 20 l of the lysate was analyzed using 11% SDS-PAGE and western 
blotting followed by ECL detection. 
 
Neuropathological study of D. melanogaster (section 5.2.3) 
The fly strains created in publication I were used to study the neuropathological 
effects of wt and mutant HYLS1 in D. melanogaster model. A new generation of 
each strain was allowed to hatch after the parents were removed and a subgroup of 
each population was collected at time points of 0, 15, 30, 35 and 45 days. The flies 
were kept in +25°C and the population in each growth tube was transferred to a new 
one every two or three days to ensure fresh food supplies. The collected flies were 
terminated with CO2, formaline-fixed and cast in paraffine blocks. The blocks were 
cut into thin slices with a microtome and stained with hematoxylin-eosin. The head 
sections were examined using an Axioplan 2 imaging microscope. 
 
Cilia staining (section 5.3.3) 
For studying the cilia structure of fibroblast cells from HLS fetuses and healthy 
controls, immunofluorescence staining with acetylated tubulin was used. The cells 
were seeded onto coverslips in 6-well plates at 1 × 106 cells per well. For 
immunofluorescence studies, the cells were fixed with 4% paraformaldehyde in PBS 
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(pH 7.3) at room temperature (RT) for 10 min and blocked and permeabilized with 
0.2% saponin/0.5% bovine serum albumin (BSA) in PBS. The cells were then 
incubated with acetylated tubulin as primary antibody for 1 hr in room temperature 
(RT). After washes, the cells were incubated with secondary antibody for 40 min in 
RT. After the staining procedure and the last washes, the cells were mounted onto 
microscope slides and the data was acquired using a Leica TCS SP confocal 
microscope. 
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5 RESULTS AND DISCUSSION 
5.1 Identification and characterization of the gene underlying HLS 
5.1.1 Defining of the critical genomic region for HLS locus (I) 
Before this study, the initial critical genomic region for HLS was mapped to 
chromosome 11q23-25, the size of the region being 8.5 cM, after which the region 
could be restricted to a 1 cM region between markers D11S933 and D11S934 
(Visapää et al. 1999). In this study, the region could be further restricted to a 904 kb 
interval using information of the ancestral haplotype and the observed high LD 
between markers D11S4158 and D11S975. This was done by analyzing 16 Finnish 
HLS families and four unrelated Finnish HLS cases and using eight markers 
(D11S1752, D11S933, D11S4158, D11S1896, D11S934, D11S4110, D11S990 and 
D11S975) over the critical region. In this 904 kb region, the following nine genes 
with known function were identified: PKNOX2, FEZ1, EI24, ITM1, CHEK1, 
ACRV1, PATE, PUS3 and DDX25 (publication I and Figure 7 on page 44). In 
addition, one hypothetical transcript, FLJ32915, was found. Mutation analyses were 
performed for all of these genes by sequencing all coding regions and flanking 
intronic regions using two controls and two affected individuals that were 
homozygotes for the characteristic haplotype of disease alleles. 
Sequencing revealed several SNPs, and these were analyzed in the whole family 
material. SNPs from eight candidate genes in this critical region were monitored for 
LD in disease alleles and one major haplotype could be found in all the analyzed 
affected chromosomes. Based on this analysis the critical region could be further 
restricted to 476 kb between genes PKNOX2 and DDX25 when ancestral 
recombinations were observed in five families. One of the SNPs in the predicted 
transcript FLJ32915 showed a highly significant P-value of 10- for LD between 
allele G and the disease phenotype. All HLS cases were homozygous for the G allele 
at this SNP, whereas all parental control alleles carried the normal A allele. The four 
cases without family members were also homozygous for this G allele. This SNP 
was the only nucleotide change to be completely co-segregating with the disease in 
the families, thus implying that it actually is the disease-causing mutation for HLS. 
Additional confirmation for the assumption that this SNP was the disease-causing 
mutation was provided by the fact that in one of the families, the father of the family 
was homozygous for all informative markers over the whole critical genomic region 
except the A to G transition in FLJ32915 for which he was heterozygous. 
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The nucleotide change found to be causative for HLS was found from a predicted 
transcript FLJ32915 and since the transcript was nameless at that time, we named 
the gene and the gene product HYLS1 (“hydrolethalus syndrome 1”). 
 5.1.2 The disease-causing mutation in HLS (I) 
The disease-causing nucleotide change in FLJ32915, now named HYLS1, was found 
to be an A to G transition (c:1166 in cDNA, NCBI code NM_145014) in exon 6 
(Figure 7). This point mutation causes one amino acid change in the HYLS1 
polypeptide where aspartic acid 211 is changed to glycine (D211G). As is described
in section 5.1.3, several studies led to the confirmation that this change is a true 
mutation. 
The homozygous form of this nucleotide change has been found altogether in 64 
diagnosed Finnish cases, these cases belonging to 47 families. Of these cases, 36 
also had samples of their parents available (25 families), the parents being the 
heterozygous carriers of the mutation. In addition, we found one suspected HLS case 
with typical symptoms that was heterozygous for the HYLS1 mutation. No additional 
mutations were found in the coding region of HYLS1. Because this fetus represents 
quite a typical HLS case, the possibility exists that this fetus indeed is a true HLS 
case, the other mutation located outside the HYLS1 exonic regions. In eight 
suspected Finnish HLS cases no mutation was found. Since we currently classify 
only cases with D211G mutation as true HLS cases, these remaining cases might 
represent some other syndrome resembling HLS or they might have the mutation for 
example in the regulatory region of HYLS1 or for example in the intronic region of 
the genomic DNA. One possibility for the mutation is also a genomic deletion. 
Unfortunately, since fresh tissue material for these cases was not available, 
screening the cDNA for the mutations was not possible. 
We also had an opportunity to sequence DNA samples from 11 non-Finnish fetuses 
and newborns with a suspected diagnosis of HLS, but no mutations in the HYLS1 
gene could be found. These cases have been pathologically similar to HLS to some 
extent, but also differing features have been found. Usually, the cases have had 
hydrocephalus and polydactyly as frequent findings. Still, it should be noted that 
these two features are quite common malformations and can be found in several 
other syndromes in addition to HLS (R. Salonen, personal communication). Also, in 
many cases, the affected having a foreign background had lived even for several 
months, whereas all the mutation-confirmed Finnish HLS cases had died at the latest 
during in the very first hours or days of their lives. This would suggest that the 
Finnish cases suffer from ultimately severe defects in their vital organs. It has been 
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suggested that the underlying cause of the variability of the phenotype between 
Finnish and especially milder foreign cases is allelic variability (de Ravel et al. 
1999; Pryde et al. 1993; Shotelersuk et al. 2001). In our opinion, though, the foreign 
cases (especially with the “mild” form of HLS) with no HYLS1 confirmed 
mutation(s) might actually represent syndromes resembling HLS but that are in fact 
genetically different. Of course, this does not exclude the possibility of allelic 
variability by yet unknown mutations in the regions surrounding HYLS1, but getting 
the answer would require not only thorough sequencing analysis of the identified 
areas of HYLS1 but extensive determination and study of the regulatory areas of the 
gene, as well. 
The population frequency of the A to G change was determined using 454 control 
individuals collected from various regions of Finland and in addition, a control panel 
of 49 individuals of mixed European descent was used. As a result, 1.1% (2/176) of 
the individuals originating from the early settlement area in western Finland carried 
the change, whereas 2.5% (7/278) of the individuals collected from the late 
settlement area in eastern and central Finland were found to carry this change. No 
carriers were identified in the European panel of control individuals. The observed 
carrier frequency in the late settlement area is a bit higher than the expected 
frequency (2%). This might be explained by the fact that as for most early 
malformation syndromes, some (maybe uncertain) cases could have been 
overlooked and remain non-diagnosed as HLS. 
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Figure 7. Schematic presentation of chromosome 11 and the 904 kb critical region for 
disease causing mutation in HLS between markers D11S4158 and D11S975. Also, the 
structure of the HYLS1 gene with six exons and the causative A to G point mutation in the 
last exon are shown. 
5.1.3 Basic characteristics of the HYLS1 gene and protein (I, unpublished) 
The HYLS1 gene 
Since the A to G transition in FLJ32915, now named HYLS1, was found to be a 
disease-causing mutation in HLS, we wanted to characterize the basic properties of 
this gene and the gene product. 
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HYLS1 covers a genomic region of approximately 17 kb with six exons in 
chromosome 11 (UCSC assembly 2006: chr11:125,258,719-125,275,750). The 
region of the gene coding for protein is composed of an open reading frame (ORF) 
of 897 nucleotides and situated entirely in exon 6, resulting in a polypeptide of 299 
amino acids. HYLS1 has several alternative transcripts, all of them having the same 
conserved translated region coded by exon 6. The most common transcripts are 
named HYLS1a (NCBI: AK127394), containing exons 2, 4 and 6 and HYLS1b 
(NCBI: BQ686872 and CB141176), containing exons 2 and 6. For a detailed picture 
of the sequence, see Figure 2 in publication I. The most possible promoter sites for 
HYLS1 were predicted using Web Promoter Scan Service (PROSCAN). According 
to the results, the two most likely promoter sites could be found from a region 3.4 kb 
upstream from the first HYLS1 exon (nucleotides -3382-3133) and inside HYLS1 in 
intron 3 (nucleotides 4626-4876).  
Although exon 6 is the only protein coding exon in HYLS1 and alternative splicing 
most likely does not affect the structure of the produced protein, the other exons 
might contain essential regulatory information that could have an effect on the 
expression level of HYLS1 in different tissues and/or developmental stages. For 
example, a 5´ untranslated region can act as an essential regulatory region for 
transcription or translation in genes with only one protein coding exon, see e.g. 
(Fukada et al. 2003; Ji et al. 2004). Since the amount of the genes identified in the 
human genome has turned out to be unexpectedly low, proteome complexity has to 
be explained through other mechanisms than merely the number of genes. 
Alternative splicing has been suggested as one of the main sources of the 
complexity, since half of the human genes have been approximated to be subjected 
to alternative splicing (Lander et al. 2001; Venter et al. 2001) and it has even been 
suggested that the majority of human transcripts are alternatively spliced (Graveley 
2001). In addition to regulation at the DNA or RNA levels, over 200 different post-
translational modifications have been identified (Banks et al. 2000), these most 
probably creating variability, too. 
When comparing the observed EST (expressed sequence tag) homologies, HYLS1a 
has been identified in several tissues, including the brain, lung, liver, kidney, uterus, 
breast, placenta, colon and in addition, in pooled germ cell tumors. HYLS1b can be 
found at least in pancreatic carcinoma and liver. We could identify these two most 
common isoforms when studying the skin fibroblast cell lines´ cDNA obtained both 
from HLS cases and healthy controls. The occurrence of these isoforms were 
confirmed from a fetal cDNA panel as well as from placental tissue obtained from a 
healthy control and an affected individual by RT-PCR analyses using primers 
crossing various HYLS1 exon boundaries. The observed fragments from PCR 
analyses corresponded to the expected sizes of HYLS1a and HYLS1b. In addition, 
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three other isoforms representing alternative splicing can be found in the NCBI and 
Celera databases. These three isoforms were not found from our study material. 
Although these isoforms were not found, it does not exclude the possibility that 
these isoforms are expressed, but maybe only in restricted stages during fetal 
development. On the contrary, HYLS1a and HYLS1b could be expressed through the 
whole fetal period. In addition to the A to G change, sequencing analysis of the 
placental RT-PCR products did not reveal any other DNA changes in an affected 
individual. 
Also, northern blot analysis was done of control and affected mRNA in order to 
monitor the possible expression level changes or splice variants of the HYLS1 gene 
in affected individuals. A transcript of approximately 1.7 kb was observed both in 
samples obtained from control and HLS cases´ fibroblasts and no significant 
difference in the steady state expression level was seen. When studying a 
commercial human fetal multiple tissue blot, the expression levels of the transcript 
were found to be highest in the brain, lung, kidney and liver. 
 
The HYLS1 protein 
After we had gathered the basic information of the HYLS1 gene, we also performed 
several in silico analyses for the amino acid sequence of HYLS1. Interestingly, 
according to the Pfam database, HYLS1 does not possess any other recognizable 
functional regions than a low complexity region between amino acids 112 and 120. 
These regions are typical for proteins that are structurally less complex and they 
have been shown to be functionally important in some proteins (Wan and Wootton 
2000; Wootton 1994). Still, they are generally not well understood (Wan and 
Wootton 2000; Wootton 1994).  HYLS1 also lacks any secretory signal or signal 
peptide. Nevertheless, some differences can be found between wild type (wt) and 
mutant protein properties in silico. When comparing the isoelectric point (pI) values 
using the Expasy tool, the pI for wt protein was 6.98, whereas for the mutant protein 
the value was 7.67, this change most probably affecting the solubility of the protein. 
In addition, the PeptideCutter program estimated an Asp-N endopeptidase cleavage 
site at polypeptide position 211 for wt HYLS1, whereas this site was altered in the 
mutant form of the protein. 
When comparing amino acid sequence orthologs of HYLS1, we found that the 
aspartic acid mutated in HLS is conserved across the species from human to C. 
elegans (see Figure 3 in publication I). Surrounding the mutated site, amino acid 
sequences in general show high conservation. These findings most probably indicate 
an important role for this mutated site and for the area surrounding it for also 
protein´s stucture and/or function. Aspartic acid is a bulky amino acid with a 
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negative charge, whereas glycine is the smallest of the amino acids with a neutral 
charge. Thus, glycine usually enables the polypeptide backbone to make different 
kinds of turns when folding. Therefore, although the mutation does not cause the 
protein to be truncated it may cause a severe defect in the correct structure and 
therefore affect the proper function of the protein. 
The D211G change in HYLS1 was predicted to be probably damaging for the protein 
when the effect of the mutation was analyzed in the PolyPhen program 
(Polymorphism Phenotyping, http://genetics.bwh.harvard.edu/pph). The classification 
steps for PolyPhen are benign, possibly damaging and probably damaging, the latter 
representing the most probability for pathogenicity of the amino acid change. We also 
analyzed the D211G change with the SIFT program (Sorting intolerant from tolerant, 
http://blocks.fhcrc.org/sift/SIFT.html) (unpublished data). In this program, substituted 
amino acids with probabilities <0.05 are predicted to affect protein function and thus, 
the substitution is considered non-tolerated. As a result of this analysis, the HYLS1 
substitution was predicted to affect the protein´s function. 
When using the SUMOplot program (http://www.abgent.com/tools/sumoplot), wt 
polypeptide sequence was found to have a high probability for a sumoylation site 
containing lysine residue two amino acids upstream of aspartic acid 211 in the HYLS1 
polypeptide sequence. In the mutated form of the polypeptide, this high probability of 
the site was lost (unpublished data). Thus, the mutation in HYLS1 might affect the 
possible sumoylation event. The small ubiquitin-like modifier, SUMO, has been a 
target of extensive study in the recent past. Although SUMO is related to ubiquitin 
which primarily targets a substrate for degradation, sumoylation regulates a substrate's 
functions mainly by post-translational modifications like altering the intracellular 
localization or protein-protein interactions. These changes in turn affect gene 
expression, signal transduction as well as genomic and chromosomal stability and 
integrity. For reviews, see e.g. (Gill 2004; Müller et al. 2001; Zhao 2007). We studied 
the binding of SUMO with HYLS1 in several experiments using overexpressed cell 
lines, both with SUMO and HYLS1 alone as well as with its interaction partners 
PIAS1 or ARIP3 added in the reaction. As a result, no interaction between HYLS1 
and SUMO could be seen (unpublished, data not shown). 
As HYLS1 was an unknown gene and protein, the in silico studies provided 
essential tools for studying the DNA and polypeptide sequence further. When using 
computer-assisted programs to predict different aspects of a DNA or polypeptide 
sequence, one should still note that the results do not provide the definitive truth of 
the DNA/protein properties and functions. Instead, the in silico results give an initial 
estimation of the feature in question that offers possibilities to perform further 
functional studies for example in cell or tissue model to verify the results. 
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As described above, many combined facts support the assumption that the A to G 
change in HYLS1 is a disease-causing mutation. Among other in silico results, this 
point mutation was found to cause an amino acid to be replaced by another, a change 
that is probably damaging to the protein. Also, the high conservation level of the 
amino acid composition at the mutation site between orthologs most probably 
indicates an important role for the mutated area in protein´s stucture and/or function. 
To further identify the consequences of the mutation, several functional analyses 
were performed, the results of which are presented in the following sections. 
5.1.4 Developmental expression of Hyls1 in mouse tissues (I) 
Mouse Hyls1 gene 
Mouse orthologs of HYLS1 were found as ESTs both from the NCBI and Celera 
databases. Mouse Hyls1 transcript was confirmed by sequencing of RT-PCR 
products using post-embryonic cDNA from mouse brain and aligning the resulted 
sequence with the human HYLS1 sequence. The predicted size for the mouse 
transcript was 2.1 kb and this was confirmed by northern blot analysis from the 
embryonic mouse tissue, where a transcript of approximately 2 kb in size was 
observed. The expression was observed at each embryonic stage in the mouse, the 
highest expression level was seen at E11. Post-embryonically, the transcript was 
seen to be expressed from P1 to six months using RT-PCR analysis. Also, the 
chromosomal position where the mouse Hyls1 can be found is syntenic to the human 
11q24 region, where human HYLS1 is situated. Mouse Hyls1 contains four exons, 
the ORF being 984 nucleotides long, this frame coding for a predicted polypeptide 
of 328 amino acids. The similarity of mouse and human ORFs was over 80% both at 
the mRNA and at the amino acid levels. Exon 4 in Hyls1 is the only translated one 
with a high similarity in the sequence with exon 6 in human HYLS1. Other Hyls1 
exons did not show significant similarity with human HYLS1 exons. 
 
In situ hybridization of Hyls1 
To characterize the spatial expression pattern of Hyls1 during mouse development, 
in situ hybridizations were performed. Embryonic sections of E12.5 and E15.5 mice 
as well as brain sections of three months old mice were used. At E15.5, expression 
could be seen in several tissues and structures, expression being particularly high in 
the developing CNS. In the cephalic region, Hyls1 was detected in the 
telencephalon, the midbrain and the medulla. Also the ganglionic eminence and the 
choroid plexus expressed Hyls1 at E15.5. In addition to these structures, expression 
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could be seen in the spinal cord and in the dorsal root ganglia in the nervous system 
area. Expression could also be seen in the neural layer of the retina. Other structures 
with Hyls1 signal were the pancreas, kidney, stomach, intestine, testis and the 
cartilage tissue of developing limbs. Expression was also strong in the 
cardiovascular and respiratory organs, especially in the epithelium of the lungs. We 
also studied E12.5 mouse embryonic sections and as a result, we could see that the 
expression pattern covered the developing brain, neural tube, olfactory and oral 
epithelium, lung epithelium, heart, cloaca, urethra and cartilage tissue. In the adult 
mouse brain, the expression could be detected in the CA1 and CA3 fields of the 
hippocampus and in addition, in the cortex. For a detailed picture of this expression 
pattern, see Figure 4 in publication I. 
Although there is a possibility that human and mouse HYLS1 proteins may not 
function identically, the observed broad expression pattern in the mouse correlates 
well with the phenotype of human HLS cases, the pattern reflecting the affected 
tissues in HLS. The expression of Hyls1 in many embryonic mouse tissues further 
strengthens the initial theory of the essential role of HYLS1 in fetal developmental 
processes in many developing organs, including the CNS. 
5.2 Characterization of the HYLS1 protein 
5.2.1 Expression and stability (I) 
Using computer assisted programs, HYLS1 was predicted to code for a 299 amino 
acid with a molecular weight of 34.4 kilodaltons (kDa). To characterize the relative 
molecular weight of HYLS1 protein, in vitro transcription and translation of an in 
vitro rabbit reticulocyte lysate system was used. As a result, both wt and D211G 
mutant constructs produced polypeptide chains of approximately 39 and 40 kDa. 
The 40 kDa polypeptide most likely represents the complete HYLS1 polypeptide, 
whereas the 39 kDa polypeptide most probably results from the use of an alternative 
translation initiation site 14 amino acids downstream from the first methionine. 
Both constructs were also expressed in COS-1 cells after which a western blot analysis 
was performed. Synthesized polypeptides were detected with the rabbit polyclonal 
anti-HYLS1 antibody, a peptide antibody that was designed against amino acids 147-
161 of the HYLS1 polypeptide. Both wt and mutant forms of HYLS1 showed 
identical expression of HYLS1 with immunopositive bands of approximately 40 kDa. 
This result well agrees with the in vitro translated polypeptides. The corresponding 
protein levels between the wt and the mutant HYLS1 form were similar. In addition to 
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these studies, a pulse-chase analysis was performed in order to study the stability of 
both polypeptides. The half-lives of both forms were about three hours and this 
analysis did not reveal any significant difference in the amount of immunoprecipitated 
polypeptides from wt and mutant constructs. 
These analyses show that both wt and mutant forms of HYLS1 are of the same size 
and that their expression levels and half-lives are identical. Thus, it can be assumed 
that the mutation in the gene does not lead to degradation of the mutated protein 
after it has been translated suggesting that the deleterious effect of the mutation is 
due to altered functional properties of the protein. 
5.2.2 Subcellular localization of HYLS1 in a cell model (I) 
As HYLS1 was a novel protein, there was no previous information on its subcellular 
localization in the cells. When the localization was determined with computer 
assisted programs, SignalP did not predict a nuclear localization signal, but 
PSORTII analysis predicted a possible nuclear localization for the polypeptide with 
a probability of 52%.  
To elucidate the localization of HYLS1 in a cell model and possible differences 
between wt and mutant forms of the protein, we transiently expressed HYLS1 in 
COS-1 cells. Wt and mutant HYLS1 constructs were also tagged with FLAG and 
Myc tags to confirm the specificity of anti-HYLS1 antibody. COS-1 cells were 
transfected either with FLAG-tagged, Myc-tagged or untagged wt or mutant HYLS1 
constructs. The immunostaining was performed with specific antibodies for the 
constructs (anti-FLAG-, anti-Myc- and rabbit anti-HYLS1 antibodies, respectively). 
The synthesized polypeptides were detected with the same rabbit polyclonal anti-
HYLS1 antibody as described in section 5.2.1. Localization of the tagged proteins 
showed the peptide antibody to be specific for HYLS1. 
As a result, cells transfected with wt form of the protein showed mostly diffuse 
cytoplasmic staining, whereas mutant polypeptides largely localized to punctate 
nuclear inclusions (Table 2, Figure 6 in publication I). The proportion of cells 
containing solely nuclear inclusions was over 40% in cells containing the mutant 
form of the protein, compared to under 2% in cells containing the wt form. Cells 
with both staining patterns were observed approximately in half of the cells in both 
groups. The dual localization pattern observed here might at least partly explain the 
in silico localization results with no solid result of either nuclear or cytoplasmic 
compartment in the cell. Differential subcellular localization is also presented in 
Figure 8. 
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After observing the differential localization of wt and mutant HYLS1 forms, we 
were also interested to see whether HYLS1 co-localizes with some of the functional 
subcellular compartments. This was performed using antibodies having known 
subcellular localization. We did not see any significant co-localization when 
comparing the subcellular localization of HYLS1 with H4A3 (lysosomes), 58K 
(Golgi apparatus) or PDI (endoplasmic reticulum). 
 
Table 2. Distribution of HYLS1 polypeptide in COS-1 cells. 
construct cytoplasmic % cytoplasmic and nuclear % nuclear % 
wt 49.4 48.8 1.8 
D211G mutant 6.2 53.0 40.7 
 
5.2.3 Localization of HYLS1 in D. melanogaster model (I) 
Subcellular localization of HYLS1 was also studied in vivo using a Drosophila 
melanogaster (fruit fly) model, an organism that does not naturally possess HYLS1 
in its genome. Wt and mutant constructs encoding human HYLS1 were 
overexpressed in the D. melanogaster third instar eye discs using a GMR-GAL4 
driver. The antibody used here was the same peptide antibody that was also used in 
overexpression cell studies (described in section 5.2.2). As the antibody proved to be 
functioning in the overexpression cell model, we were convinced that it can be used 
also in the characterization of HYLS1 in the transgenic in vivo environment. First, 
western blot analyses were performed to protein extracted from adult fly heads 
expressing wt HYLS1 and also from control flies. A band of approximately 40 kDa 
was observed from the head lysates expressing HYLS1, which corresponds to the 
size of the HYLS1 protein. No band was observed in control head lysates, as 
expected. 
The same cellular localization pattern observed in in vitro cell studies was also 
found when studying the immunostaining of larval eye discs with rabbit anti-HYLS1 
antibody for both wt and mutant forms of HYLS1. Cells expressing wt HYLS1 
largely showed cytoplasmic staining with some perinuclear inclusions and cells 
expressing the mutant form revealed a staining pattern of nuclear dot-like structures. 
Control cells containing no HYLS1 constructs showed no staining as was expected, 
as D. melanogaster does not naturally possess the HYLS1 gene. These results 
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provided further evidence of differential localization between wt and D211G mutant 
HYLS1. 
5.2.4 Analysis of nuclear export signal in HYLS1 (III) 
In HYLS1, no putative nuclear export sequences could be identified in the amino 
acid sequence in silico. However, the dual subcellular localization of HYLS1 in the 
cytoplasm and nucleus studied both in vitro and in vivo would suggest that it might, 
in addition to most probably being transported into the nucleus, also be actively 
exported from it. To test this hypothesis, HEK-293 cells were transfected with 
constructs expressing either wt or D211G mutant HYLS1 and subjected to 
leptomycin B (LMB). LBM is known to be an inhibitor of the nuclear export 
mechanism that CRM1 (or exportin 1) mediates, and CRM1 is one of the best 
characterized nuclear export receptors. After immunofluorescence microscopy, the 
proportion of cells exhibiting either a nuclear, cytoplasmic or combined nuclear and 
cytoplasmic staining pattern was measured. As a result, we observed that the 
treatment of cells with LMB (15 ng/ml) for 6 hours led to exclusively nuclear 
localization of both wt and mutant HYLS1 that significantly differed from the 
untreated state (both wt and mutant treated state versus corresponding untreated 
state p<0.001 by student´s t-test). On the contrary, without LMB treatment most of 
the wt cells had cytoplasmic localization whereas cells transfected with mutant 
construct localized both in the nucleus and cytoplasm (student´s t-test between 
untreated wt and mutant p<0.001). An example result is presented in Figure 8. 
 
 
Figure 8. HEK-293 cells transfected with a construct expressing wt HYLS1. Before LMB 
treatment HYLS1 shows predominantly cytoplasmic localization (A), whereas after the 
treatment HYLS1 is localized in the nuclei (B). 
THL — Research The Molecular Basis of  
Hydrolethalus Syndrome
5 Results and Discussion
 53 
5.2.5 Transactivation assay (III) 
On the basis of the results from several functional studies presented in the previous 
sections, we assumed that HYLS1 might have a role as a transcriptional regulator. To 
study this hypothesis, we performed a transactivation assay with luciferase reporter to 
test whether the protein possesses transactivation capacity. For this, constructs 
expressing either wt or D211G mutant HYLS1 in fusion with the Gal4-DBD as well as 
the reporter vector pG5LUC were transfected to the SH-SY5Y neuroblastoma cells. 
As a result, the wt protein was shown to activate the transcription by 9.4-fold 
compared to blank vector, whereas the mutant HYLS1 was capable of increasing the 
transactivation only by 3.4-fold. The difference between vector and wt was statistically 
significant (p-value <0.01 with student´s t-test). The same was true between vector and 
mutant (p-value <0.05). Also the difference between the wild type and mutant form of 
HYLS1 was significant with a p-value of <0.01. Therefore, we could conclude that 
HYLS1 has transactivation capacity and this capacity is significantly decreased in cells 
containing the mutant form of the protein. 
These results combined with the results of the in vitro and in vivo overexpression 
model of HYLS1 in cell studies (sections 5.2.2-5.2.4) lend support for the hypothesis 
that HYLS1 is shuttled between the nucleus and cytoplasm and that it is a protein that 
probably functions as a transcriptional regulator in cells. At present, it is known that 
many essential proteins are shuttled between the nucleus and cytoplasm to control 
their function, these including cell cycle regulators and RNA binding proteins, steroid 
hormone receptors as well as transport receptors and adaptors (Gama-Carvalho and 
Carmo-Fonseca 2001). Also, the activities of many transcription factors or cofactors 
have been reported to be controlled via nucleocytoplasmic shuttling (Gama-Carvalho 
and Carmo-Fonseca 2001; Smith and Koopman 2004). Abnormalities in the shuttling 
process may have a role for example in the development of neurodegenerative 
diseases (Chu et al. 2007). Shuttling proteins usually have both a nuclear localization 
signal (NLS) and a nuclear export signal (NES) that are used to guide the protein 
through channels formed by the nuclear pore complexes (NPCs). In some cases, the 
same amino acid sequence is used for both import and export purposes (Gama-
Carvalho and Carmo-Fonseca 2001). Although conserved forms of these signals have 
been found, some of the signals have remained uncharacterized, see e.g. (Nakielny and 
Dreyfuss 1999). No known NLS or NES was found in HYLS1 when analyzing the 
polypeptide sequence in silico. 
In addition to being transported between the nucleus and cytoplasm with the aid of 
carrier proteins, a protein can be passively diffused between these compartments 
without assisting proteins because of their small size, the size limit varying between 
40 and 60 kDa (Terry et al. 2007; Yoneda 2000). In most cases, macromolecules 
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larger than this are actively transported across the NPC (Terry et al. 2007; Yoneda 
2000). Thus, the molecular weight of HYLS1 is at the border of these two options. 
Nuclear export studies imply that HYLS1 contains a NES since LMB inhibits 
HYLS1 from getting out of nucleus. Since in silico programs did not identify any 
NES in HYLS1, the possibility exists that this signal could be either non-
conservative or situated in a fragmented form in the polypeptide sequence. The 
mutated region in HYLS1 most probably is either directly part of the NES or the 
mutation changes the conformation of the protein in a way that the NES becomes 
inactive. Entrapment of the mutated protein in the nucleus and thus the lack of the 
normal regulatory mechanism of this transcriptional regulator in cells might explain 
the diminished transactivation potential of mutant HYLS1, as well. 
Based on the results presented above, it can be hypothesized that HYLS1 is part of 
the transcription regulatory machinery. One explanation for the reduced 
transactivation potential in mutated HYLS1 could be that the mutated HYLS1 is 
unable to reach the activity level required for normal function and this leads to 
disturbed downstream pathway regulation. Another possibility is that the mutant 
HYLS1 form somehow disturbs normal developmental pathway(s) when it is 
mutated and for that reason the protein does not function normally. However, 
additional analyses would be needed to clarify the precise effect the mutation causes 
in the protein and also, whether HYLS1 directly binds to DNA and thus, acts as an 
actual transcription factor. 
5.3 Unraveling the disease pathogenesis of HLS  
5.3.1 Mutation confirmation of study samples (II) 
The main focus in publication II was to produce a detailed neuropathological picture 
of HLS for the first time. Analyses were made from archival autopsy specimens of 
21 HLS cases collected during 1981-2008. DNA from all of these cases was isolated 
and sequenced in order to verify the HYLS1 mutation status. A special extraction 
method had to be used since the tissue samples were mostly embedded in paraffin 
blocks and in addition, the sequencing process had to be done with primer pairs 
flanking a region of no more than 300 bp in order to be able to get readable DNA 
stretches for sequencing analysis because the DNA was old and fragmented. In 
addition to the 21 samples verified to be homozygous for HYLS1 mutation, one 
sample was found to be heterozygous for the mutation and in one sample, no 
mutation in HYLS1 was found. These cases were excluded from further studies. 
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5.3.2 General autopsy findings in HLS (II) 
The general autopsy findings of 21 mutation-confirmed HLS cases studied in 
publication II are listed in Table 3. 
As it can be seen in the table, the phenotypic spectrum of HLS is notably wide. 
Some of the findings are very severe already at the early stage of fetal development 
whereas some cases show only mild symptoms (see Figures 1A and 1B in 
publication II). The reason for this variation is still uncertain, but it can be 
speculated whether the spectrum is caused by the mutated form of HYLS1 alone or 
if there are also additional factors behind the phenomenon. These can include for 
example possible modifier genes (Genin et al. 2008) and/or external factors, e.g. 
environmental conditions during fetal development. 
All of the cases studied had micrognathia, i.e. a small mandible. Also a lung defect 
was a common finding with a frequency of 90% of the cases. Cleft lip or palate was 
found in about half of the cases. Other symptoms to be mentioned are hallux duplex 
that had been reported in nine cases (42%) and uterus duplex, a rare finding in 
healthy individuals that was found in over 20% of the cases. 
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5.3.3 Macroscopic neuropathological picture of HLS (II) 
Major CNS findings in HLS cases are presented in Table 4. The highly characteristic 
finding was a hydrocephalus with unique features in which the lateral ventricles 
opened into an interhemispheric space that was filled with cerebrospinal fluid. This 
kind of hydrocephalus was seen in 17 of 21 cases. A constant and a hallmark finding 
was a special kind of occipitoschisis, the cleft extending from the foramen magnum 
to form a keyhole-shaped opening in the skull base (Figure 9A). Sometimes, the 
cerebellum or the meninges bulged through the opening in the neck beneath the 
intact skin. An “open-book” phenomenon was a typical finding, formed by the 
separated cerebral hemispheres that were lying on the bottom of the skull (Figure 
9B). A large amount of cerebrospinal fluid above was discovered especially in the 
cases born in the second or third trimesters of pregnancy. The upper midline 
structures, septum pellucidum, corpus callosum, and fornicles were absent. 
Hydrocephalus is one of the most common malformations with an estimated 
incidence of 1 in 1500 births (Zhang et al. 2006) and there are many different 
possibilities for the cause. Most cerebrospinal fluid (CSF) is produced by a highly 
vascular in-growth through the ependymal lining of the brain ventricles known as 
the choroid plexus (CP) (for a review, see e.g. (Brodbelt and Stoodley 2007). In 
addition to its function as the producer of CSF, CP is an important interface between 
the peripheral blood and CSF. It has been suggested that CP is also involved in cell 
growth, axon guidance and migration of neurons in CNS via the polypeptides it 
produces (Emerich et al. 2005). It has also been shown that hydrocephalus in rats 
impairs the cortical development of the brain, the results suggesting that the 
circulating CSF and its associated factors are essential for development of the neural 
tube during embryonic development (Emerich et al. 2005). As hydrocephalus is one 
of the hallmark features in HLS, it would be interesting to study the possible role of 
excess CSF in the pathogenesis of the syndrome. Hydrocephalus can form, for 
example, due to an imbalance between the production and resorption of CSF or if its 
circulation is blocked (Carlson 2004). The precise mechanism of hydrocephalus in 
HLS or whether it is a primary or a secondary effect of HYLS1 malfunction is not 
currently known. In our in situ hybridizations performed using embryonic mouse 
sections (publication I), we could see a specific staining of CP in mouse brain. This 
result might indicate that HYLS1 expressed in CNS has a role in the production of 
CSF in the brain.  
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Figure 9. A) A key-hole like opening in the skull base of an HLS case of 33rd gestational 
week. B) Abnormal “open-book” brain structure of an HLS case of 13th gestational week. 
 
Ependymal cells lining the brain ventricles contain motile cilia, but their biological 
function has remained obscure. Ibañez-Tallon et al. (2004) have reported that 
ependymal cilia generate a laminar flow of cerebrospinal fluid through the cerebral 
aqueduct. They proved that the axonemal dynein heavy chain gene (Mdnah5) was 
specifically expressed in ependymal cells and that it is essential for ultrastructural 
and functional integrity of ependymal cilia. In Mdnah5-mutant mice, a lack of 
ependymal flow caused closure of the aqueduct and formation of hydrocephalus 
during mouse brain development (Ibanez-Tallon et al. 2004). According to these 
findings, cilia might have an essential role in cerebrospinal fluid regulation. 
The macroscopic brain architecture in HLS was also defective. The gyration of the 
brain was often grossly abnormal in the frontoparietal regions, and the temporal and 
occipital regions were found to be severely hypoplastic. Normally developed 
amygdala or hippocampi could not be found. A narrow cleft at the junction of 
thalami and rostral mesencephalon was identified, this probably representing a 
hypoplastic third ventricle. The brainstem and cerebellum were hypoplastic. The 
mesencephalon was the most normal-appearing region of the brainstem. The 
cerebellum was found to be abnormally small. 
A very interesting finding was a polyploid hypothalamic hamartoma that was 
observed in several cases. These were of considerable size in some of the cases that 
were born in the last trimester of the pregnancy. In the early fetal cases, the 
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hamartoma was more difficult to observe and in some cases, only a bulging of the 
hypothalamic plate region could be seen. According to the numerical syndromology 
studies Verloes have reported (Verloes 1995), three non-Finnish cases (Anyane-
Yeboa et al. 1987; Hingorani et al. 1991) classified as HLS all also had a 
hamartoblastoma finding in addition to other malformations similar to HLS. This 
would be an interesting small detail to be discussed when possible phenotypic 
borders are set for the foreign suspected HLS cases. 
In four of the cases (cases 6a, 6b, 9, and 12 in publication II), the main macroscopic 
finding was anencephaly (one case) or hydranencephaly (three cases) instead of the 
usually found “open-book” hydrocephalus. Two of the fetuses with hydranencephaly 
were siblings (cases 6a and 6b). Alobar or semilobar holoprosencephaly was not 
found in this study; in the HLS cases a complete interhemispheric fissure could 
always be observed, indicating hemispheric cleavage. At the moment, it is not 
known why some of the HLS cases have anencephaly or hydranencephaly instead of 
the “open-book” appearance in the brain. 
 
Cilia in HLS cells (unpublished) 
Cilia are microtubule-based hair-like organelles extending from the cell surface of 
almost all polarized cell types of the human body, the amount of cilia ranging from 
one to hundreds per cell; for a review, see e.g. (Fliegauf et al. 2007). As mentioned 
in the previous section and as discussed in several recent reports, cilia are proven to 
be highly essential structures in several body functions, cerebrospinal fluid 
regulation as one example (discussed above). Evidence about cilia being also an 
important part of central signaling mechanisms, including the SHH signaling 
pathway, have been reported (Fliegauf et al. 2007). The SHH pathway will be 
discussed further in section 5.3.7. As the normal fetal developmental events, for 
example the formation of left-right asymmetry, is also highly dependent on the 
normal ciliary function and since HLS resembles Meckel syndrome, another lethal 
malformation syndrome of the fetal period in which the cilia formation is severely 
disturbed in mutant cells (Kyttälä et al. 2006; Tallila et al. 2008), we performed 
immunofluorescence staining using skin fibroblasts from HLS cases and healthy 
controls in order to compare the formation of the cilia between the cell groups. The 
initial results showed that in contrast to Meckel syndrome, both the wt and HLS 
mutant cells contain cilia (Figure 10) (unpublished data). However, we cannot 
exclude the possibility that there is a defect of cilia to some degree in HLS cells. For 
example, in the C. elegans animal model of another ciliary disease called the Bardet-
Biedl syndrome (MIM 209900), the cilia are somewhat visible both in control and 
mutant cells but their structure is abnormal in mutant cells (Li et al. 2008). Thus, 
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more studies would be needed to find out whether detailed cilia formation is 
disturbed also in HLS. 
 
 
Figure 10. Skin fibroblast cells from both a healthy control (A) and an HLS fetus (B) show 
cilia staining (arrows). 
 
5.3.4 Microscopic neuropathological picture of HLS (II, unpublished) 
In addition to macroscopic examination of the HLS fetuses, a detailed microscopic 
study of the samples was performed using immunohistochemical stainings. 
When studying the cerebral cortex histologically, it was found to be immature with 
polymicrogyric and lissencephaly type 2 –like areas. Disorganized neuroblastic 
rosettes were also observed (Figure 11A) as were irregular and disrupted bundles of 
radial glial structures (Figure 11B). Ectopic neuroblastic rosettes could also be 
frequently observed under the cortical region, with a quite high proliferation rate 
when using MIB-1 staining. As an explanation for these rosette structures, we 
hypothesized that they could represent aberrant miniature “neural tubes”, caused by 
an abnormal signal promoting the development of the dorsal neural tube in these 
immature and disorganized regions of the fetal brain.  
Calretinin positive neuronal clusters were prominent in the superficial cortical areas. 
Because these positive cells also expressed reelin, they can be considered to be 
Cajal-Retzius cells. Reelin, a protein secreted by Cajal-Retzius cells, is essential for 
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completion of neuronal migration and cortical lamination. Abnormal amount, 
clustering and persistence of these cells have been reported in cases of 
polymicrogyria and this phenomenon is probably common in disorders related to 
defective neuronal migration (Eriksson et al. 2001). Another interesting aspect is 
that according to some studies with mouse models, the normal function of GLI3 
protein has been demonstrated to be essential for correct cortical lamination 
(Friedrichs et al. 2008; Theil 2005). This fact combined with the disturbed cortical 
structure in HLS fetuses might suggest that HYLS1 functions using a similar 
mechanism as GLI3. 
The hypothalamic hamartomas mostly consisted of neuronal cells, but also some 
glial cells were seen. In addition, some smaller, probably immature cells and 
neuropil were seen. Quite normal looking, although fragmented, choroid plexus 
structures were seen in many cases at the basal corners of the open interhemispheric 
space, and also often in the region of the fourth ventricle. The cerebellar cortex 
showed narrowing of all its layers. The basis of the pons was histologically severely 
atrophic and defects were also seen in the brain stem area. 
The histology of the spinal cord was studied in four cases (cases 2b, 9, 15 and 17 in 
publication II). The central canal was slit-like in the cervical part and the posterior 
columns were hypoplastic. One spinal cord was bifid in the ventral part, one had a 
dorsal hamartomatous bulging in its cervical part and two spinal cords had double 
central canal in the lumbar region. The motor columns were found to be quite 
normally populated. 
 
 
Figure 11. A) Immature and disorganized neuroblastic rosettes (arrows) were observed in the 
cerebral cortex of an HLS fetus at the 17th gestation week. B) Also irregular and disrupted 
bundles of radial glial structures (arrow) could be seen in the same fetal sample. 
THL — Research The Molecular Basis of  
Hydrolethalus Syndrome
5 Results and Discussion
 63 
Interestingly, in microarray analysis (see section 5.3.5), the neuropilin 2 (NRP2) 
gene was found to be downregulated by over 3-fold in HLS cells when compared to 
control cells. Neuropilins are found to function as receptors for some of the 
semaphorins, whereas semaphorins act as chemorepulsive signals in interneuron 
migration. Marin et al. used a mouse model to demonstrate that interneurons 
expressing neuropilins avoid entering the striatum, a subcortical part of the 
telencephalon, because of this repulsive signal and are thus directed to the cortex 
(Marin et al. 2001). Loss of neuropilin function, in turn, increases the number of 
interneurons that migrate into the striatum. Marin et al. concluded that their 
observations reveal a mechanism by which neuropilins mediate sorting of distinct 
neuronal populations into different brain structures, and provide evidence that, in 
addition to guiding axons, neuropilins also control neuronal migration in the central 
nervous system. Therefore, in the absence of neuropilins, the correct migration 
pattern of interneurons could also be compromised in the brains of HLS cases. Thus, 
the expression array finding nicely binds with the disrupted cortical patterning 
observed in our studies of brain architecture. 
In conclusion, the pattern of brain pathology found in the HLS cases described 
above clearly belongs to the midline patterning defects. The pattern seems to be 
unique for the hydrolethalus syndrome, combining the features of disturbed 
neurulation, forebrain patterning, and migration. As the SHH signaling pathway 
plays an essential part in fetal midline development, it is tempting to hypothesize 
that defects in HLS are caused by a defect in this pathway, too. Currently, additional 
analyses would be needed to confirm this hypothesis. The SHH pathway will be 
discussed further in section 5.3.7. 
 
Fly model of HLS neuropathology (unpublished) 
In addition to characterization of the human fetuses affected with HLS, a Drosophila 
melanogaster model of HLS generated earlier was used to determine whether any 
neuropathological changes similar to those seen in humans could be replicated when 
studying neural structures of flies expressing either wt or mutant forms of HYLS1 
(unpublished, data not shown). HYLS1 was directed to be expressed in either eye 
retina with the gmr fly line or in CNS with the elav fly line using the GAL4-UAS 
system (St Johnston 2002). As a result, no significant differences between wt and 
mutant flies were found. Some vacuolar structures of the eye and the CNS were 
observed in mutant flies, but this could be due to the strong overexpression of 
HYLS1 in these structures in some of the fly lines, rather than a specific indication 
of altered HYLS1 function. 
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5.3.5 Genome-wide gene expression analysis (III) 
Although HYLS1 was suggested to encode a transcriptional regulator, the exact 
information of the gene and the protein function was unclear. To gain additional 
clues via cellular pathways, we performed a genome-wide gene expression analysis 
of fetal fibroblast cell lines (control N=4, HLS N=3) to obtain novel data on cellular 
pathways influencing the HLS pathogenesis. For the analysis, we used the genome-
wide Affymetrix array system. After the chip data was initially analyzed, we ended 
up with altogether 802 transcripts and from this group we chose a subgroup of these 
as statistically significant to be analyzed further. 
Several pathways were found to be significantly differentially expressed between the 
control and HLS cells (Figure 12). When studying the whole data set, the difference 
in the amount of expression of the transcripts varied from -8.02 to +13.79. For the 
whole list of regulated genes, see Supplementary Table 1 in publication III. After 
examination of the gene lists with the Webgestalt program, many of the upregulated 
transcripts were found to be associated with the cell cycle regulatory cascades and 
with specific signal transduction pathways. The downregulated transcripts fell into 
the general category of lipid metabolism. 
The most upregulated genes inside the groups cell cycle regulation and signal 
transduction included dual specificity phosphatase 6 (DUSP6), platelet-derived 
growth factor alpha polypeptide (PDGFA), and mitogen-activated protein kinase 
kinase kinase 5 (MAP3K5). The fold-changes were 7.06, 3.76 and 2.92, respectively. 
Other interesting upregulated genes were for example cyclin D1 (CCND1, fold-
change 2.91), fibroblast growth factor 5 (FGF5, 2.81) and CASP8- and FADD-like 
apoptosis regulator (CFLAR, 2.63). The downregulated genes related to lipid 
metabolism included like-glycosyltransferase (LARGE, fold-change -3.54) stearoyl-
CoA desaturase (SCD, -3.50), acetyl-Coenzyme A acetyltransferase 2 (ACAT2, -
3.02), low density lipoprotein receptor (LDLR, -2.83), 7-dehydrocholesterol 
reductase (DHCR7, -2.53) and 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
(HMGCS1, -2.20) among others. Downregulated genes related to axon guidance 
included spondin 2 (SPON2, -7.15) and neuropilin 2 (NRP2, -3.19). These findings 
led to subsequent analyses that are discussed in sections 5.3.6 and 5.3.7. 
As the analyses were performed using skin fibroblast, they might not reveal all the 
essential pathways defective in the CNS and therefore, it would be interesting to use 
cell lines of neuronal cell populations, too. Unfortunately, an insufficient amount of 
the neuronal cell lines was available for these analyses. However, the findings 
acquired using the fibroblast cell lines provide us with useful additional clues for the 
process of unraveling the HYLS1 function. 
THL — Research The Molecular Basis of  
Hydrolethalus Syndrome
5 Results and Discussion
 65 
 
 
 
Figure 12. Most of the upregulated pathways (A) in HLS fibroblast cells are related to cell 
cycle regulation and signal transduction events while the downregulated pathways (B) are 
mostly involved in lipid metabolism. Significantly regulated pathways are marked with a 
gray background. Modified from the Webgestalt program output. 
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5.3.6 Cell proliferation rate and the amount of apoptosis (III) 
In the gene expression analysis, we could see upregulation of several genes involved 
in cell cycle events and thus, we wanted to study the cell cycle rate in fetal cells. We 
had an opportunity to cultivate both HLS and control cells of fetal neuronal 
progenitor cell origin. The proliferative activity of HLS and control neuronal 
progenitor cells was detected by measuring the incorporation of bromodeoxyuridine 
(BrdU) and the proliferating cells were identified by immunocytochemistry. The 
result of this assay showed that the proliferation rate of the neural progenitor cells 
was significantly elevated in the HLS cells when compared with the control cells. 
The amount of the proliferation was 7.9% in HLS cells whereas only 1.7% in control 
cells. Student´s t-test showed a statistically significant result for this study with a p-
value of <0.001. 
In agreement with the elevated cell cycle rate in neuronal cells, the microarray 
analyses showed that for example the CCND1 gene was upregulated almost by 3-
fold in HLS fibroblasts. CCND1 is an essential regulator of cell cycle events and 
when the expression level of CCND1 is abnormal, it can be part of the cancer-
causing events in tissues (Li et al. 2006b; Tashiro et al. 2007). Although tumour 
predisposition would be impossible to monitor in HLS cases, the possibility exists 
that the aspect of elevated cell cycle rate might at least partly explain the hamartoma 
findings in the brain of HLS fetuses. An interesting finding in the microarray study 
was also the upregulation of the thrombospondin 1 (THBS1) gene at the same time 
of CCND1 upregulation, since CCND1 is known to act as an inhibitor of THBS1 (Li 
et al. 2006a). A possible explanation for this phenomenon could be that due to the 
initial upregulation of THBS1 the level of CCND1 is also elevated to counteract the 
inhibitory effect of THBS1 at the protein level, or on the other hand, that the cells 
are reacting to CCND1 upregulation by also producing more THBS1. 
In addition to the proliferation assay, apoptosis was measured from the progenitor 
cells by Annexin staining and using flow cytometry. As a result, the amount of 
apoptosis in control cells was on average 25.6% while in HLS cells the apoptosis 
amount was only 8.7%. In conclusion, the apoptosis rate in HLS patient neural 
progenitor cells was highly decreased, student´s t-test giving a statistically 
significant result (p<0.05). The difference in necrotic cells between the control and 
patient cell samples was not significant. 
Remarkably, HLS neuronal progenitor cells showed a significantly decreased 
amount of apoptosis and increase in the proliferation rate. Finding of the reduced 
apoptosis rate is highly interesting because apoptosis is an essential and precisely 
controlled phenomenon of controlled cell death both in fetal development 
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(developmental programmed cell death) and in adulthood (homeostatic programmed 
cell death) (Buss et al. 2006). Apoptosis is used for example in sculpting the shapes 
of developing organs, like creating gaps between the digits in the limbs and also in 
the regulation of the amount of cells in the brain. According to an accepted theory, 
populations of neurons are produced in excess they then compete against each other 
for a limited supply of survival promoting trophic factors produced by their targets 
(Buss and Oppenheim 2004; Hua and Smith 2004). When creating animal models 
with a suppressed apoptosis rate, in many cases genetic reduction or elimination of 
cell death led to embryonic mortality or gross anatomical malformations, in some 
cases probably due to the continued proliferation of undead cells (Buss and 
Oppenheim 2004). This evidence nicely fits with the reduced amount of apoptosis in 
HLS cells and with the dramatic phenotype of the CNS and the other malformations 
observed in HLS. Still, the relationship between an elevated proliferation rate and 
the reduced rate of apoptosis needs to be studied further. It would be beneficial to 
clarify whether one of these phenomena is the primary and the other secondary 
symptom occurring during the abnormal brain development in HLS. In order to 
explain the interaction of these findings and to understand the mechanism causing 
the severe malformations in the brain, it is essential that the common denominator 
for all these findings could be found in the future. 
5.3.7 Lipid metabolism (III) 
Cholesterol level analysis 
Since the gene expression analysis showed downregulation of genes involved in 
lipid metabolism, especially related to the cholesterol pathway, we wanted to see 
whether the lipid levels between the HLS and control samples differed from each 
other. We had an opportunity to use liver samples collected at the autopsies from 
two controls and from three HLS fetuses. After the lipids were extracted from the 
cells, the concentrations of cholesterol, phospholipids and triglycerides were 
determined. As a result, the cholesterol levels in the liver tissue in HLS fetuses were 
elevated by an average of 25.3% (p<0.01 by student´s t-test) when compared to 
control samples. There was no significant difference between the two groups in 
phospholipid or triglyceride levels (p>0.05). This result suggests that there exists a 
disturbance in the hepatic sterol balance in the liver cells of HLS fetuses. This result 
is also consistent with the microarray analysis findings where differential expression 
in lipid metabolism pathway between the controls and the HLS cases was observed. 
In Smith-Lemli-Opitz syndrome (SLOS), mutations in DHCR7 lead to increased 
levels of 7-dehydrocholesterol and decreased cholesterol levels in patient serum. In 
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our gene expression arrays (section 5.3.5), DHCR7 was downregulated almost by 3-
fold when compared to the control cells and in addition, increased cholesterol levels 
were observed in HLS liver samples. The microarray analysis also revealed other 
genes involved in the cholesterol metabolism such as ACAT2, HMGCS1 and LDLR to 
be downregulated, in addition to DHCR7. These results lend support for the theory 
that in HLS fetuses, cholesterol is accumulated in the liver and this in turn would 
cause feed-back downregulation of these genes involved in the cholesterol 
metabolism. Another possibility would be receptor-mediated endocytosis of 
cholesterol in the form of low-density lipoprotein (LDL) particles from the circulation. 
An interesting aspect is that the recent studies have shown that cellular lipid rafts 
have many essential functions and among others, they play a critical role in the 
signal transduction events of the cells (Korade and Kenworthy 2008). In our study, 
the group of genes representing the function in signal transduction were upregulated. 
This finding compared with lipid rafts and lipid metabolism nicely binds the up- and 
downregulated pathways together. Further studies would be needed to elucidate 
whether disturbed HYLS1 function and thus, also abnormal cholesterol metabolism, 
might have an effect in lipid raft composition and further, in signal transduction, too. 
In the course of diagnosing SLOS, it has been reported that in addition to invasive 
methods to confirm the diagnosis of the fetus, also a non-invasive method which 
measured maternal urinary steroid levels (Jezela-Stanek et al. 2006) could be an 
option for initial analysis for the syndrome. It would be fascinating if the same kind 
of method could also be applicable in the initial analysis of HLS, especially if only 
mild symptoms can be observed in ultrasound scan. 
 
Cholesterol, Hedgehog signaling pathway and developmental disorders 
As HLS presents several defects in development, most of them belonging to the field 
of midline patterning defects, it would be interesting to consider a possible 
connection between the Hedgehog signaling pathway and HYLS1. The Hedgehog 
(HH) family of proteins is one of the key protein families in fetal development. This 
entity is currently widely studied; for reviews, see e.g. (Cohen 2003; Varjosalo and 
Taipale 2008). Pathways related to the members of this protein family pattern almost 
every aspect of the vertebrate body plan. The use of a single morphogen for such a 
wide variety of fuctions is possible because cellular responses to HH depend on the 
responding cell type, the dose of HH received, and the time cells are exposed to HH 
(Varjosalo and Taipale 2008). One of the pathways belonging to this signaling 
family is named after its critical protein Sonic hedgehog (SHH). Regulation of this 
pathway in mammals leads to the activation and repression of target genes by the 
glioma (GLI) transcription factors GLI1, GLI2 and GLI3. Abnormalities of the SHH 
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pathway lead to several human diseases, including birth defects and cancers. During 
embryonic development, the SHH gene is expressed in several places including the 
notochord, the floorplate of the neural tube, the brain, the zone of polarizing activity 
in the developing limbs, and the gut (Villavicencio et al. 2000). Mutations of SHH in 
human have been reported to cause holoprosencephaly (Monuki 2007; Roessler et 
al. 1996) and also to impair neural patterning activity (Schell-Apacik et al. 2003). 
Comparing HLS with PHS and SLOS is of special interest since the pathways where 
the disease-causing genes are functioning are known in PHS and SLOS. PHS is 
caused by mutations in the GLI3 gene, which is an essential transcription factor 
functioning in the SHH pathway. The defective gene in SLOS is DHCR7, and its 
gene product is an important part of cholesterol biosynthesis. Since the Hedgehog 
protein itself is dependent on a cholesterol residue in processing its final structure 
(Cooper et al. 2003), DHCR7 might indirectly take part in regulating the function of 
the SHH pathway. Interestingly, DHCR7 and SHH are are reported to be 
coexpressed during midline development in Xenopus embryos (Koide et al. 2006). 
Since PHS and SLOS share several similar features with HLS there is a possibility 
that HYLS1 is involved in similar kinds of molecular pathways as proteins behind 
these syndromes and thus, it is tempting to create a hypothesis where HYLS1 
directly or indirectly affects the function of the SHH signaling pathway. Since 
HYLS1 has significant transactivational capacity it could, like GLI3, function as a 
transcriptional regulator in some stage of SHH pathway. On the other hand, as cells 
derived from the HLS fetuses show downregulation of several genes related to lipid 
metabolism and as cholesterol is needed for the proper function of the SHH protein, 
HYLS1 could have an indirect effect on the SHH pathway functioning via the 
cholesterol metabolism pathway instead of being directly part of the SHH pathway. 
This is an interesting matter to be studied further. However, there is a drastic 
diffence between these syndromes and HLS this being that HLS individuals 
confirmed to have the Finmajor mutation have lived at most for some days, whereas 
individuals affected with either PHS or SLOS can survive even to adulthood. This 
would be another big question which needs to be elucidated. 
In addition to our hypothesis, also other groups have discussed about the possibility 
of some kind of relationship between HLS and the SHH pathway. Rakheja et al. 
published a case report where they had studied the sterol levels using a liver sample 
of a suspected HLS fetus and they concluded that HLS is not caused by a defect in 
post-squalene cholesterol biosynthesis (Rakheja et al. 2004). Unfortunately, at the 
time the study was published, the causative mutation for HLS was not yet known 
and thus, there is no proof whether this case truly represented HLS or not. 
Nevertheless, Rakheja et al. discuss the possibility that the gene underlying HLS 
does not affect normal post-squalene cholesterol biosynthesis but it is still part of the 
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SHH pathway and the mutated gene in HLS might be situated elsewhere in this 
pathway. After the HYLS1 mutation was published, Castori et al. suggested an 
involvement of a possible common signaling pathway between HLS and 
holoprosencephaly-diencephalic hamartoblastoma, an entity of the HLS-resembling 
symptoms where SHH signaling network could play a role in the pathogenesis 
(Castori et al. 2007). 
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6 CONCLUSIONS AND FUTURE PROSPECTS 
During this study, the gene and the protein underlying HLS, a severe fetal 
malformation syndrome, were identified and characterized. Also several functional 
analyses were performed to further unravel the pathogenesis of HLS. As the point 
mutation in the HYLS1 gene leading to one amino acid change in the protein can cause 
such a severe phenotype as in this syndrome, the outcome of the amino acid change 
itself must have drastic consequences in the protein structure and/or in the function of 
the protein. Further, HYLS1 must have an essential and central role in one or several 
pathways directing the correct embryonic and fetal development in humans. Most 
probably, the underlying cause for such a severe syndrome containing several 
malformations is a cascade phenomenon where the mutated protein causes abnormal 
events in one or several pathways; this further leads to defects in downstream 
pathways, as well. It should also be noted that HYLS1 might have different functions 
depending on the tissue and/or the developmental stage it is expressed in. 
The results of this study have provided significant new information on the molecular 
and cellular defects that HYLS1 mutation causes during embryonic and fetal 
development. The study also unraveled important aspects of the HYLS1 function 
itself, and based on the results, the conclusion that HYLS1 is a transcriptional 
regulator, which is transported between the cell nucleus and cytoplasm could be 
drawn. These findings will form a basis for future studies of HLS. Although being a 
rare syndrome, the results of the multiple analyses reported in this thesis offer useful 
information about the molecular events and pathways, the proper function of which 
are required in normal embryonic and fetal development, too. The underlying 
mechanism and the pathway in which HYLS1 functions, as well as the interaction 
partners it functions with, would be important and interesting to study in the future. 
It would be interesting to further delineate the effects of the abnormal cholesterol 
metabolism in HLS cases and the effect of this phenomenon on cellular events. 
Another intriguing aspect for future studies would be the characterization of even 
minor malformations possibly appearing in HYLS1 mutation carriers. Although 
when the disease is transmitted autosomal recessively it is thought that the carriers 
are healthy, some subtle findings occurring among carriers have been discussed in 
the course of some syndromes. Since the phenotypic spectrum in HLS is so wide, it 
would be also fascinating to determine the external factors possibly affecting the 
phenotype of HLS during fetal development, such as the sterol levels of mothers 
during pregnancy. 
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